@prefix fhir: <http://hl7.org/fhir/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

# - resource -------------------------------------------------------------------

<http://hl7.eu/fhir/ig/gravitate-health/Bundle/995d3971-b899-43bf-857d-98c26634796d> a fhir:Bundle;
  fhir:nodeRole fhir:treeRoot;
  fhir:Resource.id [ fhir:value "995d3971-b899-43bf-857d-98c26634796d"];
  fhir:Resource.meta [
     fhir:Meta.versionId [ fhir:value "1" ];
     fhir:Meta.lastUpdated [ fhir:value "2021-06-25T22:39:35.186+00:00"^^xsd:dateTime ]
  ];
  fhir:Bundle.identifier [
     fhir:Identifier.system [ fhir:value "http://ema.europa.eu/fhir/identifier/documentid" ];
     fhir:Identifier.value [ fhir:value "3103a561-4b54-4e02-9cd0-eceb190a0602" ]
  ];
  fhir:Bundle.type [ fhir:value "document"];
  fhir:Bundle.timestamp [ fhir:value "2021-06-25T22:39:32+00:00"^^xsd:dateTime];
  fhir:Bundle.entry [
     fhir:index 0;
     fhir:Bundle.entry.fullUrl [ fhir:value "urn:uuid:be0cf64a-79ae-427b-bd11-06e24f7798ab" ];
     fhir:Bundle.entry.resource <urn:uuid:be0cf64a-79ae-427b-bd11-06e24f7798ab>
  ] .

<urn:uuid:be0cf64a-79ae-427b-bd11-06e24f7798ab> a fhir:Composition;
  fhir:Resource.language [ fhir:value "no"];
  fhir:DomainResource.text [
     fhir:Narrative.status [ fhir:value "generated" ];
     fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"no\" lang=\"no\"><p><b>Generated Narrative</b></p><p><b>status</b>: final</p><p><b>type</b>: <span title=\"Codes: {http://spor.ema.europa.eu/v1/lists/100000155531 100000155532}\">PREPARATOMTALE</span></p><p><b>date</b>: 2021-02-01</p><p><b>author</b>: <span></span></p><p><b>title</b>: BARE TEST FORMÃ…L - Acme irbesartan 75 mg, tablets</p><h3>RelatesTos</h3><table class=\"grid\"><tr><td>-</td><td><b>Code</b></td><td><b>Target[x]</b></td></tr><tr><td>*</td><td>appends</td><td>id: d6492916-2a98-4ea8-a938-324d5e5c471b</td></tr></table></div>"
  ];
  fhir:DomainResource.contained [
     a fhir:Binary;
     fhir:index 0;
     fhir:Resource.id [ fhir:value "stylesheet0" ];
     fhir:Binary.contentType [ fhir:value "text/css" ];
     fhir:Binary.data [ fhir:value "<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
@font-face
	{font-family:SimSun;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:"Calibri Light";
	panose-1:2 15 3 2 2 2 4 3 2 4;}
@font-face
	{font-family:Verdana;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:"Segoe UI";
	panose-1:2 11 5 2 4 2 4 2 2 3;}
@font-face
	{font-family:"\@SimSun";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:"\@MS Mincho";
	panose-1:2 2 6 9 4 2 5 8 3 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
h1
	{mso-style-link:"Heading 1 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h4
	{mso-style-link:"Heading 4 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-align:justify;
	text-justify:inter-ideograph;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h5
	{mso-style-link:"Heading 5 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
h6
	{mso-style-link:"Heading 6 Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.85pt;
	text-indent:-70.85pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoHeading7, li.MsoHeading7, div.MsoHeading7
	{mso-style-link:"Heading 7 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:21.25pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading8, li.MsoHeading8, div.MsoHeading8
	{mso-style-link:"Heading 8 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.5pt;
	text-indent:-21.25pt;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeading9, li.MsoHeading9, div.MsoHeading9
	{mso-style-link:"Heading 9 Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoIndex1, li.MsoIndex1, div.MsoIndex1
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex2, li.MsoIndex2, div.MsoIndex2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex3, li.MsoIndex3, div.MsoIndex3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex4, li.MsoIndex4, div.MsoIndex4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex5, li.MsoIndex5, div.MsoIndex5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex6, li.MsoIndex6, div.MsoIndex6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex7, li.MsoIndex7, div.MsoIndex7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex8, li.MsoIndex8, div.MsoIndex8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoIndex9, li.MsoIndex9, div.MsoIndex9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:99.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc1, li.MsoToc1, div.MsoToc1
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc2, li.MsoToc2, div.MsoToc2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc3, li.MsoToc3, div.MsoToc3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:22.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc4, li.MsoToc4, div.MsoToc4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:33.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc5, li.MsoToc5, div.MsoToc5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:44.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc6, li.MsoToc6, div.MsoToc6
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:55.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc7, li.MsoToc7, div.MsoToc7
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:66.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc8, li.MsoToc8, div.MsoToc8
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:77.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToc9, li.MsoToc9, div.MsoToc9
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:88.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNormalIndent, li.MsoNormalIndent, div.MsoNormalIndent
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoFootnoteText, li.MsoFootnoteText, div.MsoFootnoteText
	{mso-style-link:"Footnote Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoCommentText, li.MsoCommentText, div.MsoCommentText
	{mso-style-name:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	mso-style-link:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoHeader, li.MsoHeader, div.MsoHeader
	{mso-style-link:"Header Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Arial",sans-serif;}
p.MsoFooter, li.MsoFooter, div.MsoFooter
	{mso-style-link:"Footer Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.MsoIndexHeading, li.MsoIndexHeading, div.MsoIndexHeading
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoCaption, li.MsoCaption, div.MsoCaption
	{mso-style-name:"Caption\,Caption 12pt\,Caption 12pt+\,Caption-FUSA\,figure";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:center;
	page-break-after:avoid;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoTof, li.MsoTof, div.MsoTof
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoEnvelopeAddress, li.MsoEnvelopeAddress, div.MsoEnvelopeAddress
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:2.0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoEnvelopeReturn, li.MsoEnvelopeReturn, div.MsoEnvelopeReturn
	{margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Calibri Light",sans-serif;}
span.MsoCommentReference
	{font-family:"Times New Roman",serif;}
span.MsoPageNumber
	{font-family:"Times New Roman",serif;}
p.MsoEndnoteText, li.MsoEndnoteText, div.MsoEndnoteText
	{mso-style-link:"Endnote Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoToa, li.MsoToa, div.MsoToa
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:11.0pt;
	text-indent:-11.0pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMacroText, li.MsoMacroText, div.MsoMacroText
	{mso-style-link:"Macro Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoToaHeading, li.MsoToaHeading, div.MsoToaHeading
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoList, li.MsoList, div.MsoList
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpFirst, li.MsoListCxSpFirst, div.MsoListCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpMiddle, li.MsoListCxSpMiddle, div.MsoListCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListCxSpLast, li.MsoListCxSpLast, div.MsoListCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet, li.MsoListBullet, div.MsoListBullet
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpFirst, li.MsoListBulletCxSpFirst, div.MsoListBulletCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpMiddle, li.MsoListBulletCxSpMiddle, div.MsoListBulletCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBulletCxSpLast, li.MsoListBulletCxSpLast, div.MsoListBulletCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber, li.MsoListNumber, div.MsoListNumber
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpFirst, li.MsoListNumberCxSpFirst, div.MsoListNumberCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpMiddle, li.MsoListNumberCxSpMiddle, div.MsoListNumberCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumberCxSpLast, li.MsoListNumberCxSpLast, div.MsoListNumberCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2, li.MsoList2, div.MsoList2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpFirst, li.MsoList2CxSpFirst, div.MsoList2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpMiddle, li.MsoList2CxSpMiddle, div.MsoList2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList2CxSpLast, li.MsoList2CxSpLast, div.MsoList2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3, li.MsoList3, div.MsoList3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpFirst, li.MsoList3CxSpFirst, div.MsoList3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpMiddle, li.MsoList3CxSpMiddle, div.MsoList3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList3CxSpLast, li.MsoList3CxSpLast, div.MsoList3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4, li.MsoList4, div.MsoList4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpFirst, li.MsoList4CxSpFirst, div.MsoList4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpMiddle, li.MsoList4CxSpMiddle, div.MsoList4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList4CxSpLast, li.MsoList4CxSpLast, div.MsoList4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5, li.MsoList5, div.MsoList5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpFirst, li.MsoList5CxSpFirst, div.MsoList5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpMiddle, li.MsoList5CxSpMiddle, div.MsoList5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoList5CxSpLast, li.MsoList5CxSpLast, div.MsoList5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	text-indent:-14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2, li.MsoListBullet2, div.MsoListBullet2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpFirst, li.MsoListBullet2CxSpFirst, div.MsoListBullet2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpMiddle, li.MsoListBullet2CxSpMiddle, div.MsoListBullet2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet2CxSpLast, li.MsoListBullet2CxSpLast, div.MsoListBullet2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3, li.MsoListBullet3, div.MsoListBullet3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpFirst, li.MsoListBullet3CxSpFirst, div.MsoListBullet3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpMiddle, li.MsoListBullet3CxSpMiddle, div.MsoListBullet3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet3CxSpLast, li.MsoListBullet3CxSpLast, div.MsoListBullet3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4, li.MsoListBullet4, div.MsoListBullet4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpFirst, li.MsoListBullet4CxSpFirst, div.MsoListBullet4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpMiddle, li.MsoListBullet4CxSpMiddle, div.MsoListBullet4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet4CxSpLast, li.MsoListBullet4CxSpLast, div.MsoListBullet4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5, li.MsoListBullet5, div.MsoListBullet5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpFirst, li.MsoListBullet5CxSpFirst, div.MsoListBullet5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpMiddle, li.MsoListBullet5CxSpMiddle, div.MsoListBullet5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListBullet5CxSpLast, li.MsoListBullet5CxSpLast, div.MsoListBullet5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2, li.MsoListNumber2, div.MsoListNumber2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpFirst, li.MsoListNumber2CxSpFirst, div.MsoListNumber2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpMiddle, li.MsoListNumber2CxSpMiddle, div.MsoListNumber2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber2CxSpLast, li.MsoListNumber2CxSpLast, div.MsoListNumber2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3, li.MsoListNumber3, div.MsoListNumber3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpFirst, li.MsoListNumber3CxSpFirst, div.MsoListNumber3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpMiddle, li.MsoListNumber3CxSpMiddle, div.MsoListNumber3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber3CxSpLast, li.MsoListNumber3CxSpLast, div.MsoListNumber3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.75in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4, li.MsoListNumber4, div.MsoListNumber4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpFirst, li.MsoListNumber4CxSpFirst, div.MsoListNumber4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpMiddle, li.MsoListNumber4CxSpMiddle, div.MsoListNumber4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber4CxSpLast, li.MsoListNumber4CxSpLast, div.MsoListNumber4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.0in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5, li.MsoListNumber5, div.MsoListNumber5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpFirst, li.MsoListNumber5CxSpFirst, div.MsoListNumber5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpMiddle, li.MsoListNumber5CxSpMiddle, div.MsoListNumber5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListNumber5CxSpLast, li.MsoListNumber5CxSpLast, div.MsoListNumber5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:1.25in;
	text-indent:-.25in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTitle, li.MsoTitle, div.MsoTitle
	{mso-style-link:"Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.MsoClosing, li.MsoClosing, div.MsoClosing
	{mso-style-link:"Closing Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoSignature, li.MsoSignature, div.MsoSignature
	{mso-style-link:"Signature Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:212.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText, li.MsoBodyText, div.MsoBodyText
	{mso-style-link:"Body Text Char";
	margin:0in;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent, li.MsoBodyTextIndent, div.MsoBodyTextIndent
	{mso-style-link:"Body Text Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue, li.MsoListContinue, div.MsoListContinue
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpFirst, li.MsoListContinueCxSpFirst, div.MsoListContinueCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpMiddle, li.MsoListContinueCxSpMiddle, div.MsoListContinueCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinueCxSpLast, li.MsoListContinueCxSpLast, div.MsoListContinueCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2, li.MsoListContinue2, div.MsoListContinue2
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpFirst, li.MsoListContinue2CxSpFirst, div.MsoListContinue2CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpMiddle, li.MsoListContinue2CxSpMiddle, div.MsoListContinue2CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue2CxSpLast, li.MsoListContinue2CxSpLast, div.MsoListContinue2CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:28.3pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3, li.MsoListContinue3, div.MsoListContinue3
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpFirst, li.MsoListContinue3CxSpFirst, div.MsoListContinue3CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpMiddle, li.MsoListContinue3CxSpMiddle, div.MsoListContinue3CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue3CxSpLast, li.MsoListContinue3CxSpLast, div.MsoListContinue3CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:42.45pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4, li.MsoListContinue4, div.MsoListContinue4
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpFirst, li.MsoListContinue4CxSpFirst, div.MsoListContinue4CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpMiddle, li.MsoListContinue4CxSpMiddle, div.MsoListContinue4CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue4CxSpLast, li.MsoListContinue4CxSpLast, div.MsoListContinue4CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:56.6pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5, li.MsoListContinue5, div.MsoListContinue5
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpFirst, li.MsoListContinue5CxSpFirst, div.MsoListContinue5CxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpMiddle, li.MsoListContinue5CxSpMiddle, div.MsoListContinue5CxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListContinue5CxSpLast, li.MsoListContinue5CxSpLast, div.MsoListContinue5CxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:70.75pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoMessageHeader, li.MsoMessageHeader, div.MsoMessageHeader
	{mso-style-link:"Message Header Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:56.7pt;
	text-indent:-56.7pt;
	line-height:13.0pt;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSubtitle, li.MsoSubtitle, div.MsoSubtitle
	{mso-style-link:"Subtitle Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:center;
	line-height:13.0pt;
	font-size:12.0pt;
	font-family:"Calibri Light",sans-serif;}
p.MsoSalutation, li.MsoSalutation, div.MsoSalutation
	{mso-style-link:"Salutation Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoDate, li.MsoDate, div.MsoDate
	{mso-style-link:"Date Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent, li.MsoBodyTextFirstIndent, div.MsoBodyTextFirstIndent
	{mso-style-link:"Body Text First Indent Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextFirstIndent2, li.MsoBodyTextFirstIndent2, div.MsoBodyTextFirstIndent2
	{mso-style-link:"Body Text First Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	text-indent:10.5pt;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoteHeading, li.MsoNoteHeading, div.MsoNoteHeading
	{mso-style-link:"Note Heading Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText2, li.MsoBodyText2, div.MsoBodyText2
	{mso-style-link:"Body Text 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyText3, li.MsoBodyText3, div.MsoBodyText3
	{mso-style-link:"Body Text 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent2, li.MsoBodyTextIndent2, div.MsoBodyTextIndent2
	{mso-style-link:"Body Text Indent 2 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:200%;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBodyTextIndent3, li.MsoBodyTextIndent3, div.MsoBodyTextIndent3
	{mso-style-link:"Body Text Indent 3 Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:14.15pt;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Times New Roman",serif;}
p.MsoBlockText, li.MsoBlockText, div.MsoBlockText
	{margin-top:0in;
	margin-right:1.0in;
	margin-bottom:6.0pt;
	margin-left:1.0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
a:link, span.MsoHyperlink
	{font-family:"Times New Roman",serif;
	color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{font-family:"Times New Roman",serif;
	color:purple;
	text-decoration:underline;}
p.MsoDocumentMap, li.MsoDocumentMap, div.MsoDocumentMap
	{mso-style-link:"Document Map Char";
	margin:0in;
	line-height:13.0pt;
	font-size:8.0pt;
	font-family:"Segoe UI",sans-serif;}
p.MsoPlainText, li.MsoPlainText, div.MsoPlainText
	{mso-style-link:"Plain Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoAutoSig, li.MsoAutoSig, div.MsoAutoSig
	{mso-style-link:"E-mail Signature Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
address
	{mso-style-link:"HTML Address Char";
	margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-style:italic;}
pre
	{mso-style-link:"HTML Preformatted Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Courier New";}
p.MsoCommentSubject, li.MsoCommentSubject, div.MsoCommentSubject
	{mso-style-link:"Comment Subject Char";
	margin:0in;
	line-height:13.0pt;
	font-size:10.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	line-height:13.0pt;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;}
p.MsoNoSpacing, li.MsoNoSpacing, div.MsoNoSpacing
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoRMPane, li.MsoRMPane, div.MsoRMPane
	{margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.MsoQuote, li.MsoQuote, div.MsoQuote
	{mso-style-link:"Quote Char";
	margin-top:10.0pt;
	margin-right:.6in;
	margin-bottom:8.0pt;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#404040;
	font-style:italic;}
p.MsoIntenseQuote, li.MsoIntenseQuote, div.MsoIntenseQuote
	{mso-style-link:"Intense Quote Char";
	margin-top:.25in;
	margin-right:.6in;
	margin-bottom:.25in;
	margin-left:.6in;
	text-align:center;
	line-height:13.0pt;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	color:#5B9BD5;
	font-style:italic;}
p.MsoBibliography, li.MsoBibliography, div.MsoBibliography
	{margin:0in;
	line-height:13.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.MsoTocHeading, li.MsoTocHeading, div.MsoTocHeading
	{margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	line-height:13.0pt;
	page-break-after:avoid;
	font-size:16.0pt;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading4Char
	{mso-style-name:"Heading 4 Char";
	mso-style-link:"Heading 4";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading5Char
	{mso-style-name:"Heading 5 Char";
	mso-style-link:"Heading 5";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading6Char
	{mso-style-name:"Heading 6 Char";
	mso-style-link:"Heading 6";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.Heading7Char
	{mso-style-name:"Heading 7 Char";
	mso-style-link:"Heading 7";
	font-family:"Times New Roman",serif;}
span.Heading8Char
	{mso-style-name:"Heading 8 Char";
	mso-style-link:"Heading 8";
	font-family:"Times New Roman",serif;}
span.FooterChar
	{mso-style-name:"Footer Char";
	mso-style-link:Footer;
	font-family:"Arial",sans-serif;}
span.HeaderChar
	{mso-style-name:"Header Char";
	mso-style-link:Header;
	font-family:"Arial",sans-serif;}
p.MemoHeaderStyle, li.MemoHeaderStyle, div.MemoHeaderStyle
	{mso-style-name:MemoHeaderStyle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:70.9pt;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Arial",sans-serif;
	font-variant:small-caps;
	font-weight:bold;}
span.BodyTextChar
	{mso-style-name:"Body Text Char";
	mso-style-link:"Body Text";}
span.CommentTextChar
	{mso-style-name:"Comment Text Char\,Car17 Char\,Car17 Car Char\,Car17 Car Car Char\,Char13 Char\,Char13 Car Char\,Char13 Car Car Char";
	mso-style-link:"Comment Text\,Car17\,Car17 Car\,Car17 Car Car\,Char13\,Char13 Car\,Char13 Car Car";
	font-family:"Times New Roman",serif;}
p.EMEAEnBodyText, li.EMEAEnBodyText, div.EMEAEnBodyText
	{mso-style-name:"EMEA En Body Text";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:SimSun;}
p.BodytextAgency, li.BodytextAgency, div.BodytextAgency
	{mso-style-name:"Body text \(Agency\)";
	mso-style-link:"Body text \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.BodytextAgencyChar
	{mso-style-name:"Body text \(Agency\) Char";
	mso-style-link:"Body text \(Agency\)";
	font-family:"Verdana",sans-serif;}
p.DraftingNotesAgency, li.DraftingNotesAgency, div.DraftingNotesAgency
	{mso-style-name:"Drafting Notes \(Agency\)";
	mso-style-link:"Drafting Notes \(Agency\) Char";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
span.DraftingNotesAgencyChar
	{mso-style-name:"Drafting Notes \(Agency\) Char";
	mso-style-link:"Drafting Notes \(Agency\)";
	font-family:"Courier New";
	color:#339966;
	font-style:italic;}
p.NormalAgency, li.NormalAgency, div.NormalAgency
	{mso-style-name:"Normal \(Agency\)";
	mso-style-link:"Normal \(Agency\) Char";
	margin:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableheadingrowsAgency, li.TableheadingrowsAgency, div.TableheadingrowsAgency
	{mso-style-name:"Table heading rows \(Agency\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
p.TabletextrowsAgency, li.TabletextrowsAgency, div.TabletextrowsAgency
	{mso-style-name:"Table text rows \(Agency\)";
	margin:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
span.NormalAgencyChar
	{mso-style-name:"Normal \(Agency\) Char";
	mso-style-link:"Normal \(Agency\)";
	font-family:"Verdana",sans-serif;}
span.CommentSubjectChar
	{mso-style-name:"Comment Subject Char";
	mso-style-link:"Comment Subject";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Revisjon1, li.Revisjon1, div.Revisjon1
	{mso-style-name:Revisjon1;
	margin:0in;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
p.Default, li.Default, div.Default
	{mso-style-name:Default;
	margin:0in;
	text-autospace:none;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Table, li.Table, div.Table
	{mso-style-name:Table;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:141.8pt;
	text-indent:-56.7pt;
	page-break-after:avoid;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.TWNormal, li.TWNormal, div.TWNormal
	{mso-style-name:"TW Normal";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;
	color:black;}
p.Listeavsnitt1, li.Listeavsnitt1, div.Listeavsnitt1
	{mso-style-name:Listeavsnitt1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpFirst, li.Listeavsnitt1CxSpFirst, div.Listeavsnitt1CxSpFirst
	{mso-style-name:Listeavsnitt1CxSpFirst;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpMiddle, li.Listeavsnitt1CxSpMiddle, div.Listeavsnitt1CxSpMiddle
	{mso-style-name:Listeavsnitt1CxSpMiddle;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
p.Listeavsnitt1CxSpLast, li.Listeavsnitt1CxSpLast, div.Listeavsnitt1CxSpLast
	{mso-style-name:Listeavsnitt1CxSpLast;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman",serif;}
span.FootnoteTextChar
	{mso-style-name:"Footnote Text Char";
	mso-style-link:"Footnote Text";
	font-family:"Times New Roman",serif;}
p.TableFootnote, li.TableFootnote, div.TableFootnote
	{mso-style-name:"Table Footnote";
	margin:0in;
	font-size:8.0pt;
	font-family:"Arial",sans-serif;}
p.TableText, li.TableText, div.TableText
	{mso-style-name:"Table Text";
	mso-style-link:"Table Text Char";
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;}
p.TableTitle, li.TableTitle, div.TableTitle
	{mso-style-name:"Table Title";
	mso-style-link:"Table Title Char";
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:6.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	page-break-after:avoid;
	font-size:9.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.TableTextChar
	{mso-style-name:"Table Text Char";
	mso-style-link:"Table Text";
	font-family:"Verdana",sans-serif;}
span.TableTitleChar
	{mso-style-name:"Table Title Char";
	mso-style-link:"Table Title";
	font-family:"Times New Roman",serif;
	font-weight:bold;}
p.Body, li.Body, div.Body
	{mso-style-name:Body;
	mso-style-link:"Body Car";
	margin-top:3.0pt;
	margin-right:0in;
	margin-bottom:3.0pt;
	margin-left:0in;
	text-align:justify;
	text-justify:inter-ideograph;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;}
span.BodyCar
	{mso-style-name:"Body Car";
	mso-style-link:Body;
	font-family:"Times New Roman",serif;}
p.QRDBookmark, li.QRDBookmark, div.QRDBookmark
	{mso-style-name:"QRD Bookmark";
	margin:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	text-transform:uppercase;
	font-weight:bold;}
p.BodytextEMA, li.BodytextEMA, div.BodytextEMA
	{mso-style-name:"Body text \(EMA\)";
	margin-top:0in;
	margin-right:0in;
	margin-bottom:7.0pt;
	margin-left:0in;
	line-height:14.0pt;
	font-size:9.0pt;
	font-family:"Verdana",sans-serif;}
p.QRDBookmark2, li.QRDBookmark2, div.QRDBookmark2
	{mso-style-name:"QRD Bookmark2";
	margin:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Times New Roman",serif;
	font-weight:bold;}
span.BodyText2Char
	{mso-style-name:"Body Text 2 Char";
	mso-style-link:"Body Text 2";}
span.BodyText3Char
	{mso-style-name:"Body Text 3 Char";
	mso-style-link:"Body Text 3";}
span.BodyTextFirstIndentChar
	{mso-style-name:"Body Text First Indent Char";
	mso-style-link:"Body Text First Indent";}
span.BodyTextIndentChar
	{mso-style-name:"Body Text Indent Char";
	mso-style-link:"Body Text Indent";}
span.BodyTextFirstIndent2Char
	{mso-style-name:"Body Text First Indent 2 Char";
	mso-style-link:"Body Text First Indent 2";}
span.BodyTextIndent2Char
	{mso-style-name:"Body Text Indent 2 Char";
	mso-style-link:"Body Text Indent 2";}
span.BodyTextIndent3Char
	{mso-style-name:"Body Text Indent 3 Char";
	mso-style-link:"Body Text Indent 3";}
span.ClosingChar
	{mso-style-name:"Closing Char";
	mso-style-link:Closing;}
span.DateChar
	{mso-style-name:"Date Char";
	mso-style-link:Date;}
span.DocumentMapChar
	{mso-style-name:"Document Map Char";
	mso-style-link:"Document Map";
	font-family:"Segoe UI",sans-serif;}
span.E-mailSignatureChar
	{mso-style-name:"E-mail Signature Char";
	mso-style-link:"E-mail Signature";}
span.EndnoteTextChar
	{mso-style-name:"Endnote Text Char";
	mso-style-link:"Endnote Text";}
span.Heading9Char
	{mso-style-name:"Heading 9 Char";
	mso-style-link:"Heading 9";
	font-family:"Calibri Light",sans-serif;}
span.HTMLAddressChar
	{mso-style-name:"HTML Address Char";
	mso-style-link:"HTML Address";
	font-style:italic;}
span.HTMLPreformattedChar
	{mso-style-name:"HTML Preformatted Char";
	mso-style-link:"HTML Preformatted";
	font-family:"Courier New";}
span.IntenseQuoteChar
	{mso-style-name:"Intense Quote Char";
	mso-style-link:"Intense Quote";
	color:#5B9BD5;
	font-style:italic;}
span.MacroTextChar
	{mso-style-name:"Macro Text Char";
	mso-style-link:"Macro Text";
	font-family:"Courier New";}
span.MessageHeaderChar
	{mso-style-name:"Message Header Char";
	mso-style-link:"Message Header";
	font-family:"Calibri Light",sans-serif;
	background:#CCCCCC;}
span.NoteHeadingChar
	{mso-style-name:"Note Heading Char";
	mso-style-link:"Note Heading";}
span.PlainTextChar
	{mso-style-name:"Plain Text Char";
	mso-style-link:"Plain Text";
	font-family:"Courier New";}
span.QuoteChar
	{mso-style-name:"Quote Char";
	mso-style-link:Quote;
	color:#404040;
	font-style:italic;}
span.SalutationChar
	{mso-style-name:"Salutation Char";
	mso-style-link:Salutation;}
span.SignatureChar
	{mso-style-name:"Signature Char";
	mso-style-link:Signature;}
span.SubtitleChar
	{mso-style-name:"Subtitle Char";
	mso-style-link:Subtitle;
	font-family:"Calibri Light",sans-serif;}
span.TitleChar
	{mso-style-name:"Title Char";
	mso-style-link:Title;
	font-family:"Calibri Light",sans-serif;
	font-weight:bold;}
p.No-numheading3Agency, li.No-numheading3Agency, div.No-numheading3Agency
	{mso-style-name:"No-num heading 3 \(Agency\)";
	mso-style-link:"No-num heading 3 \(Agency\) Char";
	margin-top:14.0pt;
	margin-right:0in;
	margin-bottom:11.0pt;
	margin-left:0in;
	page-break-after:avoid;
	font-size:11.0pt;
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
span.No-numheading3AgencyChar
	{mso-style-name:"No-num heading 3 \(Agency\) Char";
	mso-style-link:"No-num heading 3 \(Agency\)";
	font-family:"Verdana",sans-serif;
	font-weight:bold;}
 /* Page Definitions */
 @page WordSection1
	{size:595.35pt 842.0pt;
	margin:56.7pt 70.9pt 56.7pt 70.9pt;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>"^^xsd:base64Binary ]
  ];
  fhir:DomainResource.extension [
     fhir:index 0;
     fhir:Extension.url [ fhir:value "http://ema.europa.eu/fhir/extension/dummyValidationReference" ];
     fhir:Extension.valueReference [
       fhir:Reference.reference [ fhir:value "#stylesheet0" ]
     ]
  ];
  fhir:Composition.status [ fhir:value "final"];
  fhir:Composition.type [
     fhir:CodeableConcept.coding [
       fhir:index 0;
       fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/lists/100000155531" ];
       fhir:Coding.code [ fhir:value "100000155532" ];
       fhir:Coding.display [ fhir:value "PREPARATOMTALE" ]
     ]
  ];
  fhir:Composition.subject [
     fhir:Reference.identifier [
       fhir:Identifier.system [ fhir:value "http://spor.ema.europa.eu/v2/marketing-authorisation-numbers" ];
       fhir:Identifier.value [ fhir:value "EMEA/H/C/000142" ]
     ]
  ];
  fhir:Composition.date [ fhir:value "2021-02-01"^^xsd:date];
  fhir:Composition.author [
     fhir:index 0;
     fhir:Reference.identifier [
       fhir:Identifier.system [ fhir:value "http://spor.ema.europa.eu/v1/100000000005" ];
       fhir:Identifier.value [ fhir:value "2222" ]
     ]
  ];
  fhir:Composition.title [ fhir:value "BARE TEST FORMÃ…L - Acme irbesartan 75 mg, tablets"];
  fhir:Composition.relatesTo [
     fhir:index 0;
     fhir:Composition.relatesTo.code [ fhir:value "appends" ];
     fhir:Composition.relatesTo.targetIdentifier [
       fhir:Identifier.system [ fhir:value "http://ema.europa.eu/fhir/identifier/documentid" ];
       fhir:Identifier.value [ fhir:value "d6492916-2a98-4ea8-a938-324d5e5c471b" ]
     ]
  ];
  fhir:Composition.section [
     fhir:index 0;
     fhir:Element.id [ fhir:value "dd73476d-11a5-4ca6-8cd7-398851990760" ];
     fhir:Composition.section.title [ fhir:value "PREPARATOMTALE" ];
     fhir:Composition.section.code [
       fhir:CodeableConcept.coding [
         fhir:index 0;
         fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
         fhir:Coding.code [ fhir:value "1" ];
         fhir:Coding.display [ fhir:value "PREPARATOMTALE" ]
       ]
     ];
     fhir:Composition.section.section [
       fhir:index 0;
       fhir:Element.id [ fhir:value "4af9071e-08ed-49e1-8e94-f5751e5287ed" ];
       fhir:Composition.section.title [ fhir:value "1.       LEGEMIDLETS NAVN" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "3" ];
           fhir:Coding.display [ fhir:value "1. LEGEMIDLETS NAVN" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Acme Product 30 mg enterotabletter</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Acme Product 120 mg enterotabletter</span>\n                                </p>\n                                \n                                \n                            </div>"
       ]
     ], [
       fhir:index 1;
       fhir:Element.id [ fhir:value "7f61983d-3508-46c6-96f7-f069c3c544a3" ];
       fhir:Composition.section.title [ fhir:value "2.       KVALITATIV OG KVANTITATIV SAMMENSETNING" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "4" ];
           fhir:Coding.display [ fhir:value "2. KVALITATIV OG KVANTITATIV SAMMENSETNING" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Hver enterotablett inneholder 30 mg dimetylfumarat.</span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Hver enterotablett inneholder 120 mg dimetylfumarat.</span>\n                                </p>\n                                \n                            </div>"
       ];
       fhir:Composition.section.section [
         fhir:index 0;
         fhir:Element.id [ fhir:value "07a757b3-2ee0-4b50-8501-d009425d000f" ];
         fhir:Composition.section.title [ fhir:value "Hjelpestoff med kjent effekt" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "7" ];
             fhir:Coding.display [ fhir:value "Hjelpestoff(er) med kjent effekt" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Hver enterotablett inneholder 34,2 mg laktose (som monohydrat).</span>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Hver enterotablett inneholder 136,8 mg laktose (som monohydrat).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">For fullstendig liste over hjelpestoffer, se pkt. 6.1.</span>\n                                    </p>\n                                    \n                                    \n                                </div>"
         ]
       ]
     ], [
       fhir:index 2;
       fhir:Element.id [ fhir:value "4a2a8397-7ff0-4b3b-a3fd-25396bfbbf83" ];
       fhir:Composition.section.title [ fhir:value "3.       LEGEMIDDELFORM" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "8" ];
           fhir:Coding.display [ fhir:value "3. LEGEMIDDELFORM" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Enterotablett.</span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Hvit, filmdrasjert, rund, bikonveks tablett med en diameter pÃ¥ omtrent 6,8 mm. </span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">BlÃ¥, filmdrasjert, rund, bikonveks tablett med en diameter pÃ¥ omtrent 11,6 mm. </span>\n                                </p>\n                                \n                                \n                            </div>"
       ]
     ], [
       fhir:index 3;
       fhir:Element.id [ fhir:value "f2d48864-01c6-415a-9841-867b35715dff" ];
       fhir:Composition.section.title [ fhir:value "4.       KLINISKE OPPLYSNINGER" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "9" ];
           fhir:Coding.display [ fhir:value "4. KLINISKE OPPLYSNINGER" ]
         ]
       ];
       fhir:Composition.section.section [
         fhir:index 0;
         fhir:Element.id [ fhir:value "dc99f499-3c44-4337-aa3d-26e3d9c0d0bc" ];
         fhir:Composition.section.title [ fhir:value "4.1     Indikasjoner" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "10" ];
             fhir:Coding.display [ fhir:value "4.1 Indikasjon(er)" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product er indisert til behandling av moderat til alvorlig plakkpsoriasis hos voksne som har behov for systemisk medisinsk behandling. </span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 1;
         fhir:Element.id [ fhir:value "fd5ee14d-0a47-4a6e-89a3-a22fc6e1a614" ];
         fhir:Composition.section.title [ fhir:value "4.2     Dosering og administrasjonsmÃ¥te" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "11" ];
             fhir:Coding.display [ fhir:value "4.2 Dosering og administrasjonsmÃ¥te" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"margin-left:28.35pt;text-indent:-28.35pt;line-height:  normal;page-break-after:avoid\" class=\"MsoNormal\"/>\n                                    <p style=\"text-indent:-1.35pt;line-height:normal;page-break-after:  avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product er beregnet til bruk under veiledning og tilsyn av en lege som har erfaring innen diagnostisering og behandling av psoriasis.</span>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                </div>"
         ];
         fhir:Composition.section.section [
           fhir:index 0;
           fhir:Element.id [ fhir:value "80703ee9-c748-429d-bcb8-c3d84f8ebc3c" ];
           fhir:Composition.section.title [ fhir:value "Dosering" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "12" ];
               fhir:Coding.display [ fhir:value "Dosering" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">For Ã¥ bedre toleransen anbefales det Ã¥ begynne behandlingen med en lav startdose med gradvis Ã¸kning. I den fÃ¸rste uken skal Acme Product 30 mg tas Ã©n gang daglig (1 tablett om kvelden). I den andre uken skal Acme Product 30 mg tas to ganger daglig (1 tablett om morgenen og 1 om kvelden). I den tredje uken skal Acme Product 30 mg tas tre ganger daglig (1 tablett om morgenen, 1 midt pÃ¥ dagen, og 1 om kvelden). Fra den fjerde uken skal behandlingen endres til bare 1 Acme Product 120 mg tablett om kvelden. Denne dosen Ã¸kes deretter med 1 Acme Product 120 mg tablett per uke pÃ¥ ulike tider av dÃ¸gnet i de neste 5 ukene, som vist i tabellen nedenfor. Maksimal tillatt daglig dose er 720 mg (3 x 2 tabletter Acme Product 120 mg).</span>\n                                        </p>\n                                        \n                                        <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\" style=\"width:100.0%;border-collapse:collapse\" class=\"MsoNormalTable\">\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border:solid windowtext 1.0pt;    border-bottom:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Uke</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"62%\" style=\"width:62.5%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Antall tabletter</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:solid windowtext 1.0pt;    border-left:none;border-bottom:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Total daglig dose (mg)</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    \n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Morgen</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Midt pÃ¥ dagen</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:solid windowtext 1.0pt;    border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Kveld</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">med dimetylfumarat </span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"4\" width=\"72%\" style=\"width:72.92%;border-top:none;    border-left:solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;    border-right:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\"/>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">30</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">60</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">3</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">90</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"4\" width=\"72%\" style=\"width:72.92%;border-top:none;border-left:    solid windowtext 1.0pt;border-bottom:solid windowtext 1.0pt;border-right:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\"/>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:11.55pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">4</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:11.55pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">120</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.65pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">5</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">0</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.65pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">240</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:16.15pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">6</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:16.15pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">360</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:12.1pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">7</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:12.1pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">480</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border-top:none;border-left:solid windowtext 1.0pt;    border-bottom:none;border-right:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt;    height:13.25pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">8</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">1</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border:none;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:13.25pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">600</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"10%\" style=\"width:10.42%;border:solid windowtext 1.0pt;border-top:    none;padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">9+</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"20%\" style=\"width:20.84%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">2</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"27%\" style=\"width:27.08%;border-top:none;border-left:none;    border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt;height:15.85pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span lang=\"NO-BOK\">720</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                        </table>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Hvis en bestemt dose ikke tolereres, kan den midlertidig reduseres til sist tolererte dose.</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Hvis behandlingseffekt observeres fÃ¸r maksimaldosen er nÃ¥dd, er det ikke nÃ¸dvendig med ytterligere Ã¸kning av dosen. Etter at en klinisk relevant forbedring av hudlesjoner er oppnÃ¥dd, skal det vurderes en gradvis reduksjon av den daglige dosen av Acme Product til vedlikeholdsdosen som kreves hos den enkelte person.</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Doseringsmodifikasjoner kan ogsÃ¥ vÃ¦re nÃ¸dvendig ved observasjon av unormale laboratorieparametre (se pkt. 4.4).</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <i>\n                                                <span lang=\"NO-BOK\">Eldre pasienter</span>\n                                            </i>\n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Kliniske studier av Acme Product inkluderte ikke et tilstrekkelig antall pasienter i alderen 65 Ã¥r og over for Ã¥ kunne avgjÃ¸re hvorvidt de responderer annerledes sammenlignet med pasienter under 65 Ã¥r (se pkt. 5.2). Basert pÃ¥ farmakologien til dimetylfumarat, </span>\n                                            <span lang=\"NO-BOK\">er</span>\n                                            <span lang=\"NO-BOK\">et behov for justering av dosen hos eldre</span>\n                                            <span lang=\"NO-BOK\">ikke forventet</span>\n                                            <span lang=\"NO-BOK\">.</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <i>\n                                                <span lang=\"NO-BOK\">Nedsatt nyrefunksjon</span>\n                                            </i>\n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Ingen dosejustering er nÃ¸dvendig hos pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 5.2). Acme Product er ikke undersÃ¸kt hos pasienter med alvorlig nedsatt nyrefunksjon, og bruk av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <i>\n                                                <span lang=\"NO-BOK\">Nedsatt leverfunksjon</span>\n                                            </i>\n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Ingen dosejustering er nÃ¸dvendig hos pasienter med mild til moderat nedsatt leverfunksjon (se pkt. 5.2). Acme Product er ikke undersÃ¸kt hos pasienter med alvorlig nedsatt leverfunksjon, og bruken av Acme Product er kontraindisert hos disse pasientene (se pkt. 4.3).</span>\n                                        </p>\n                                        \n                                    </div>"
           ];
           fhir:Composition.section.section [
             fhir:index 0;
             fhir:Element.id [ fhir:value "c9f25cf2-76f8-4f46-9e79-df85bb5185ed" ];
             fhir:Composition.section.title [ fhir:value "Pediatrisk populasjon" ];
             fhir:Composition.section.code [
               fhir:CodeableConcept.coding [
                 fhir:index 0;
                 fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
                 fhir:Coding.code [ fhir:value "13" ];
                 fhir:Coding.display [ fhir:value "Pediatrisk populasjon" ]
               ]
             ];
             fhir:Composition.section.text [
               fhir:Narrative.status [ fhir:value "additional" ];
               fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                            <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                <span lang=\"NO-BOK\">Sikkerhet og effekt av Acme Product hos den pediatriske populasjonen under en alder pÃ¥ 18 Ã¥r har ikke blitt fastslÃ¥tt. Det finnes ingen tilgjengelige data for Acme Product hos den pediatriske populasjonen.</span>\n                                            </p>\n                                            <p style=\"line-height:normal;text-autospace:none\" class=\"MsoNormal\"/>\n                                        </div>"
             ]
           ]
         ], [
           fhir:index 1;
           fhir:Element.id [ fhir:value "82cfd9b0-45eb-46d7-921b-57ff3afd01c9" ];
           fhir:Composition.section.title [ fhir:value "AdministrasjonsmÃ¥te" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "14" ];
               fhir:Coding.display [ fhir:value "AdministrasjonsmÃ¥te" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Acme Product er til oral bruk. Acme Product-tablettene skal svelges hele med vÃ¦ske under eller rett etter et mÃ¥ltid.</span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\"/>\n                                            \n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Drasjeringen pÃ¥ enterotablettene er designet til Ã¥ forhindre mageirritasjon. Derfor skal tablettene ikke knuses, deles, opplÃ¸ses eller tygges. </span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ]
       ], [
         fhir:index 2;
         fhir:Element.id [ fhir:value "c7ff6012-3955-41e9-829f-03258aec52c3" ];
         fhir:Composition.section.title [ fhir:value "4.3     Kontraindikasjoner" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "16" ];
             fhir:Coding.display [ fhir:value "4.3 Kontraindikasjoner" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt;page-break-after:avoid\" class=\"Listeavsnitt1\">\n                                        <span style=\"font-size:11.0pt;font-family:Symbol\" lang=\"NO-BOK\">-</span>\n                                        <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">OverfÃ¸lsomhet overfor virkestoffet eller overfor noen av hjelpestoffene listet opp i pkt. 6.1. </span>\n                                    </p>\n                                    <p style=\"margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt\" class=\"Listeavsnitt1\">\n                                        <span style=\"font-size:11.0pt;font-family:Symbol\" lang=\"NO-BOK\">-</span>\n                                        <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">Alvorlige gastrointestinale sykdommer.</span>\n                                    </p>\n                                    <p style=\"margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt\" class=\"Listeavsnitt1\">\n                                        <span style=\"font-size:11.0pt;font-family:Symbol\" lang=\"NO-BOK\">-</span>\n                                        <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">Alvorlig nedsatt lever- eller nyrefunksjon.</span>\n                                    </p>\n                                    <p style=\"margin-top:0in;margin-right:0in;margin-bottom:  0in;margin-left:28.35pt;text-indent:-28.35pt\" class=\"Listeavsnitt1\">\n                                        <span style=\"font-size:11.0pt;font-family:Symbol\" lang=\"NO-BOK\">-</span>\n                                        <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">Graviditet og amming.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 3;
         fhir:Element.id [ fhir:value "590abf58-3378-437f-9015-57675c2a6b60" ];
         fhir:Composition.section.title [ fhir:value "4.4     Advarsler og forsiktighetsregler" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "17" ];
             fhir:Coding.display [ fhir:value "4.4 Advarsler og forsiktighetsregler" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Hematologi</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product kan redusere antall leukocytter og lymfocytter (se pkt. 4.8). Det har ikke blitt undersÃ¸kt hos pasienter med underliggende lavt leukocytt- eller lymfocyttall.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">FÃ¸r </span>\n                                        </i>\n                                        <i>\n                                            <span lang=\"NO-BOK\">behandling</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">FÃ¸r oppstart av behandling med Acme Product, bÃ¸r en ny </span>\n                                        <span lang=\"NO-BOK\">fullstendig blodtelling</span>\n                                        <span lang=\"NO-BOK\">(herunder\ndifferensialtelling og blodplater) vÃ¦re tilgjengelig. Behandlingen skal ikke\ninitieres hvis leukopeni under 3,0 x 10\n                                            <sup>9</sup>/l, lymfopeni under 1,0 x 10\n                                            <sup>9</sup>/l\neller andre patologiske resultater identifiseres.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Under behandling</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Under behandling skal en fullstendig blodtelling med differensialtelling utfÃ¸res hver 3. mÃ¥ned. Det kreves tiltak ved fÃ¸lgende forhold:</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" id=\"bffaa942-5ceb-40b6-9e61-5ff98c72b82a\" class=\"MsoNormal\"/>\n                                    <i>\n                                        <span lang=\"NO-BOK\">Leukopeni:</span>\n                                    </i>\n                                    \n                                    <p style=\"line-height:normal\" id=\"bffaa942-5ceb-40b6-9e61-5ff98c72b82a\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Hvis det blir funnet en markert nedgang i totalt antallleukocytter, bÃ¸r situasjonen overvÃ¥kes nÃ¸ye og behandling med Acme Product bÃ¸r avbrytesved nivÃ¥er under 3,0 x 10\n                                            <sup>9</sup>/l.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" id=\"4c859ed4-dc2a-460d-bd1e-11830edbfffa\" class=\"MsoNormal\"/>\n                                    <i>\n                                        <span lang=\"NO-BOK\">Lymfopeni:</span>\n                                    </i>\n                                    \n                                    <p style=\"line-height:normal\" id=\"4c859ed4-dc2a-460d-bd1e-11830edbfffa\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Hvis lymfocyttnivÃ¥et faller under 1,0 x 10\n                                            <sup>9</sup>/l, men erâ‰¥ 0,7 x 10\n                                            <sup>9</sup>/l, skal blodovervÃ¥kning utfÃ¸res mÃ¥nedlig inntilnivÃ¥er returnerer til 1,0 x 10\n                                            <sup>9</sup>/l eller hÃ¸yere ved to pÃ¥fÃ¸lgendeblodprÃ¸ver, og fra dette tidspunktet kan overvÃ¥kningen igjen utfÃ¸res hver 3.mÃ¥ned.\n                                        </span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Hvis\nlymfocyttnivÃ¥et faller under 0,7 x 10\n                                            <sup>9</sup>/l, mÃ¥ blodprÃ¸ven gjentas, og\nhvis nivÃ¥ene bekreftes Ã¥ vÃ¦re under 0,7 x 10\n                                            <sup>9</sup>, mÃ¥ behandlingen\nstoppes umiddelbart.\n                                        </span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Pasienter som utvikler lymfopeni, skal overvÃ¥kes etter Ã¥ ha avsluttet behandlingen inntil lymfocyttnivÃ¥et har gÃ¥tt tilbake til normalomrÃ¥det (se pkt. 4.8).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Andre hematologiske sykdommer</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Behandlingen skal avbrytes og det anbefales Ã¥ utvise forsiktighet hvis andre patologiske resultater forekommer. I alle fall skal blodnivÃ¥ene overvÃ¥kes inntil verdiene har gÃ¥tt tilbake til normalomrÃ¥det.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Infeksjoner</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product er en immunmodulator og kan pÃ¥virke hvordan immunsystemet reagerer pÃ¥ infeksjoner. For pasienter med eksisterende infeksjoner av klinisk relevans, skal legen avgjÃ¸re om behandling med Acme Product fÃ¸rst skal initieres nÃ¥r infeksjonen er over. Hvis en pasient utvikler en infeksjon under behandlingen med Acme Product, skal en utsettelse av behandlingen vurderes, og fordelene og risikoene skal revurderes fÃ¸r behandlingen pÃ¥begynnes pÃ¥ nytt. Pasienter som mottar Acme Product skal instrueres til Ã¥ rapportere symptomer pÃ¥ infeksjon til en lege.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Opportunistiske infeksjoner / progressiv multifokal leukoencefalopati (PML)</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Tilfeller av opportunistiske infeksjoner, spesielt progressiv multifokal leukoencefalopati (PML) har blitt rapporter med andre dimetylfumaratholdige legemidler (se pkt. 4.8). PML er en opportunistisk infeksjon forÃ¥rsaket av John-Cunningham-virus (JCV) som kan vÃ¦re dÃ¸delig eller forÃ¥rsake alvorlige funksjonshemminger. PML er sannsynligvis forÃ¥rsaket av en kombinasjon av faktorer.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">En tidligere infeksjon med JCV anses som en forutsetning for utvikling av PML. Risikofaktorer kan inkludere tidligere immunsuppressiv behandling og eksistensen av visse samtidige sykdommer (slik som autoimmune sykdommer eller ondartede hematologiske tilstander). Et modifisert eller svekket immunsystem, samt genetiske eller miljÃ¸messige faktorer kan ogsÃ¥ utgjÃ¸re risikofaktorer.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Vedvarende moderat eller alvorlig lymfopeni i lÃ¸pet av behandling med dimetylfumarat anses ogsÃ¥ som en risikofaktor for PML. Pasienter som utvikler lymfopeni skal overvÃ¥kes for tegn og symptomer pÃ¥ opportunistiske infeksjoner, spesielt symptomer som tyder pÃ¥ PML. Typiske symptomer assosiert med PML er mangfoldige, blir verre over dager til uker og inkluderer progressiv svakhet pÃ¥ Ã©n side av kroppen eller klumsethet i lemmene, synsforstyrrelse og endringer i tankegang, minne og orientering, noe som fÃ¸rer til forvirring og personlighetsforandringer. Hvis det mistenkes PML, skal behandlingen med Acme Product stoppes umiddelbart og ytterligere egnede nevrologiske og radiologiske undersÃ¸kelser gjennomfÃ¸res.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Tidligere og samtidig behandling med immunsuppressive eller immunmodulerende behandlinger</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det finnes begrensede data tilgjengelig om effekten og sikkerheten til Acme Product hos pasienter som tidligere har blitt behandlet med immunsuppressive eller immunmodulerende behandlinger. NÃ¥r pasienter bytter fra slike behandlinger til Acme Product, skal halveringstiden og virkemÃ¥ten til den andre behandlingen vurderes for Ã¥ unngÃ¥ additive virkninger pÃ¥ immunsystemet.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det finnes ingen tilgjengelige data om effekten og sikkerheten til Acme Product nÃ¥r det tas samtidig med andre immunsuppressive eller immunmodulerende behandlinger (se pkt. 4.5).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Eksisterende gastrointestinal sykdom</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product har ikke blitt studert hos pasienter med eksisterende gastrointestinal sykdom. Acme Product er kontraindisert hos pasienter med alvorlig gastrointestinal sykdom (se pkt. 4.3). Gastrointestinal toleranse kan forbedres ved Ã¥ fÃ¸lge dosetitreringsplanen ved oppstart av Acme Product-behandlingen og ved Ã¥ ta Acme Product med mat (se pkt. 4.2 og 4.8).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Nyrefunksjon</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Siden eliminasjon via nyrene spiller en mindre rolle i Acme Products plasmaclearance, er det lite sannsynlig at nedsatt nyrefunksjon ville innvirke pÃ¥ de farmakokinetiske egenskapene, og det forventes derfor at en dosejustering ikke er nÃ¸dvendig for pasienter med mild til moderat nedsatt nyrefunksjon (se pkt. 4.2 og 5.2). </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">I lÃ¸pet av den placebokontrollerte, kliniske fase III-studien ble det ikke observert noen svekking av nyrefunksjon under behandling pÃ¥ tvers av behandlingsgruppene. Acme Product har imidlertid ikke blitt undersÃ¸kt hos pasienter med alvorlig nedsatt nyrefunksjon, og noen tilfeller av nyretoksisitet har blitt rapportert under overvÃ¥kning etter markedsfÃ¸ring med fumarsyreestere. Dermed er Acme Product kontraindisert hos pasienter med alvorlig nedsatt nyrefunksjon (se pkt. 4.3). </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Nyrefunksjon (f.eks. kreatinin, blodureanitrogen og urinanalyse) skal sjekkes fÃ¸r behandlingsstart og hver 3. mÃ¥ned deretter. I tilfelle av en klinisk relevant endring i nyrefunksjon, spesielt i fravÃ¦r av alternative forklaringer, bÃ¸r dosereduksjon eller behandlingsseponering vurderes. </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Fanconi-syndrom</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Tidlig diagnostisering av Fanconi-syndrom og seponering av Acme Product-behandling er viktig for Ã¥ forhindre start av nedsatt nyrefunksjon og osteomalasi, da syndromet vanligvis er reversibelt. De viktigste tegnene er: proteinuri, glukosuri (med normale blodsukkernivÃ¥er), hyperaminoaciduri og fosfaturi (mulig samtidig med hypofosfatemi). Progresjon kan involvere symptomer som polyuri, polydipsi og proksimal muskelsvakhet. I sjeldne tilfeller kan hypofosfatemisk osteomalasi med ikke-lokaliserte skjelettsmerter, forhÃ¸yet alkalisk fosfatase i serum og stressfraktuer oppstÃ¥. Det er viktig Ã¥ merke seg at Fanconi-syndrom kan forekomme uten forhÃ¸yede kreatininnivÃ¥er eller lav glomerulÃ¦r filtreringshastighet. I tilfelle uklare symptomer skal Fanconi-syndromet vurderes, og egnede undersÃ¸kelser mÃ¥ utfÃ¸res.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Leverfunksjon</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product har ikke blitt studert hos pasienter med alvorlig nedsatt leverfunksjon og er kontraindisert hos disse pasientene (se pkt. 4.3).</span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det anbefales Ã¥ overvÃ¥ke leverfunksjon (ASAT, ALAT, gamma-GT, AP) fÃ¸r behandlingsstart og hver 3. mÃ¥ned deretter, siden Ã¸kning av leverenzymer har blitt observert hos enkelte pasienter i fase III-studien. Skulle det oppstÃ¥ en klinisk relevant endring i leverparametrene, spesielt i fravÃ¦r av alternative forklaringer, bÃ¸r dosereduksjon eller behandlingsseponering vurderes. </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">RÃ¸dme/flushing</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Pasienter bÃ¸r gjÃ¸res oppmerksom pÃ¥ at de sannsynligvis vil oppleve rÃ¸dme de fÃ¸rste ukene de tar Acme Product (se pkt. 4.8). </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Laktose</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product inneholder laktose. Pasienter med sjeldne arvelige problemer med galaktoseintoleranse, total laktasemangel eller glukose-galaktose-malabsorpsjon, bÃ¸r ikke ta dette legemidlet.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 4;
         fhir:Element.id [ fhir:value "beb6b712-37af-432a-901f-ab710741e677" ];
         fhir:Composition.section.title [ fhir:value "4.5     Interaksjon med andre legemidler og andre former for interaksjon" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "20" ];
             fhir:Coding.display [ fhir:value "4.5 Interaksjon med andre legemidler og andre former for interaksjon" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ingen interaksjonsstudier er blitt utfÃ¸rt.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Acme Product bÃ¸r derfor brukes med forsiktighet i kombinasjon med annen systemisk psoriasisbehandling (f.eks. metotreksat, retinoider, psoralener, ciklosporin, immunsuppressiva eller cytostatika) (se pkt. 4.4). Samtidig bruk av andre fumarsyrederivater under behandlingen med Acme Product bÃ¸r unngÃ¥s (topikale eller systemiske). </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Samtidig behandling med nyretoksiske stoffer (f.eks. metotreksat, ciklosporin, aminoglykosider, diuretika, NSAID-er eller litium) kan Ã¸ke potensialet for nyrebivirkninger (f.eks. proteinuri) hos pasienter som tar Acme Product.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">I tilfelle av alvorlig eller langvarig diarÃ© under behandling med Acme Product, kan absorpsjonen av andre legemidler pÃ¥virkes. Forsiktighet bÃ¸r utvises nÃ¥r legemidler med en smal terapeutisk indeks som krever absorpsjon i tarmen skal foreskrives. Effekten til orale prevensjonsmidler kan vÃ¦re redusert, og bruken av et alternativt barriereprevensjonsmiddel anbefales for Ã¥ forhindre mulig prevensjonssvikt (se forskrivningsinformasjon for oralt prevensjonsmiddel).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Inntak av store mengder sterke alkoholholdige drikkevarer (mer enn 30 vol. % alkohol) skal unngÃ¥s, da dette kan fÃ¸re til Ã¸kt opplÃ¸sningshastighet for Acme Product og derfor kan Ã¸ke frekvensen av gastrointestinale bivirkninger.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Vaksinering under behandling med Acme Product har ikke blitt studert. Immunsuppressjon er en risikofaktor for bruk av levende vaksiner. Risikoen ved vaksinering skal vurderes opp mot fordelen.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det finnes ingen tegn pÃ¥ Acme Product-interaksjon med cytokrom P450 og de mest vanlige effluks- og opptakstransportÃ¸rene, dermed forventes ingen interaksjoner med legemidler som metaboliseres eller transporteres av disse systemene (se pkt. 5.2)</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 5;
         fhir:Element.id [ fhir:value "b769313d-03f5-4684-bedf-6c423bb88dc5" ];
         fhir:Composition.section.title [ fhir:value "4.6     Fertilitet, graviditet og amming" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "22" ];
             fhir:Coding.display [ fhir:value "4.6 Fertilitet, graviditet og amming" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoCommentText\">\n                                        \n                                            <span style=\"font-size:11.0pt\" lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoCommentText\">\n                                        \n                                            <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">Fertile kvinner</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoCommentText\">\n                                        <span style=\"font-size:11.0pt\" lang=\"NO-BOK\">Acme Product er ikke anbefalt hos fertile kvinner som ikke bruker egnet prevensjon. Hos pasienter som opplever diarÃ© under Acme Product-behandling, kan effekten av orale prevensjonsmidler vÃ¦re redusert, og det kan vÃ¦re nÃ¸dvendig med barrieremetoder for prevensjon i tillegg (se pkt. 4.5).</span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoCommentText\">\n                                        \n                                            <span style=\"font-size:11.0pt\" lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                </div>"
         ];
         fhir:Composition.section.section [
           fhir:index 0;
           fhir:Element.id [ fhir:value "e60acf54-e90b-4d06-971a-5219abe3df44" ];
           fhir:Composition.section.title [ fhir:value "Graviditet" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "23" ];
               fhir:Coding.display [ fhir:value "Graviditet" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Det foreligger begrenset mengde data pÃ¥ bruk av dimetylfumarat hos gravide kvinner. Studier pÃ¥ dyr har vist reproduksjonstoksisitet (se pkt. 5.3). Acme Product er kontraindisert ved graviditet (se pkt. 4.3). </span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\"/>\n                                            \n                                        </p>\n                                    </div>"
           ]
         ], [
           fhir:index 1;
           fhir:Element.id [ fhir:value "60cdd509-a45c-4a68-ab36-32bda631bddd" ];
           fhir:Composition.section.title [ fhir:value "Amming" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "24" ];
               fhir:Coding.display [ fhir:value "Amming" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span style=\"color:black\" lang=\"NO-BOK\">Det er ukjent om </span>\n                                            <span lang=\"NO-BOK\">dimetylfumarat\n                                                <span style=\"color:black\">/metabolitter blir skilt ut i morsmelk hos mennesker. En risiko for nyfÃ¸dte eller spedbarn som ammes kan ikke </span>utelukkes\n                                                <span style=\"color:black\">.</span>Derfor er Acme Product kontraindisert ved amming (se\npkt. 4.3).\n                                            </span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoCommentText\"/>\n                                    </div>"
           ]
         ], [
           fhir:index 2;
           fhir:Element.id [ fhir:value "3edf109d-a075-49d3-9e8e-291af2f7af8a" ];
           fhir:Composition.section.title [ fhir:value "Fertilitet" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "25" ];
               fhir:Coding.display [ fhir:value "Fertilitet" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Det foreligger ingen data for mennesker eller dyr pÃ¥ effekten av Acme Product pÃ¥ fertilitet. </span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ]
       ], [
         fhir:index 6;
         fhir:Element.id [ fhir:value "8ede57fa-b7f5-40aa-8b99-8782edf4914e" ];
         fhir:Composition.section.title [ fhir:value "4.7     PÃ¥virkning av evnen til Ã¥ kjÃ¸re bil og bruke maskiner" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "26" ];
             fhir:Coding.display [ fhir:value "4.7 PÃ¥virkning av evnen til Ã¥ kjÃ¸re bil og bruke maskiner" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det er ikke gjennomfÃ¸rt noen studier av evnen til Ã¥ kjÃ¸re bil og bruke maskiner. Acme Product kan ha </span>\n                                        <span lang=\"NO-BOK\">en </span>\n                                        <span lang=\"NO-BOK\">liten pÃ¥virkning pÃ¥ evnen til Ã¥ kjÃ¸re bil og bruke maskiner. Svimmelhet og tretthet kan forekomme etter administrering av Acme Product (se pkt. 4.8).</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 7;
         fhir:Element.id [ fhir:value "779ba6b9-7eeb-47ed-891d-8245b11c1093" ];
         fhir:Composition.section.title [ fhir:value "4.8     Bivirkninger" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "27" ];
             fhir:Coding.display [ fhir:value "4.8 Bivirkninger" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Sammendrag av sikkerhetsprofilen</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">De vanligste bivirkningene observert med Acme Product i den kliniske fase III-studien (1102) hos psoriasispasienter var gastrointestinale hendelser (62,7 %), rÃ¸dme (20,8 %) og lymfopeni (10 %). De fleste bivirkningene ble ansett for Ã¥ vÃ¦re milde og fÃ¸rte ikke til seponering av studiebehandlingen. De eneste bivirkningene som fÃ¸rte til seponering av behandling for &gt;5 % av pasientene var gastrointestinale reaksjoner. For overvÃ¥kningsanbefalinger og klinisk hÃ¥ndtering av bivirkninger, se pkt. 4.4. </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Bivirkningstabell</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">FÃ¸lgende er en liste over bivirkninger som pasienter opplevde under behandling med Acme Product i lÃ¸pet av den kliniske studien og med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Bivirkningsfrekvensen er definert ved hjelp av fÃ¸lgende konvensjon: svÃ¦rt vanlige (â‰¥ 1/10), vanlige (â‰¥ 1/100 til &lt;1/10), mindre vanlige (â‰¥ 1/1000 til &lt;1/100), sjeldne (â‰¥ 1/10 000 til &lt;1/1000), svÃ¦rt sjeldne (&lt;1/10 000) og ikke kjent (kan ikke anslÃ¥s utfra tilgjengelige data). </span>\n                                    </p>\n                                    \n                                    <table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-collapse:collapse;border:none\" class=\"MsoNormalTable\">\n                                        <thead>\n                                            <tr>\n                                                <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;     padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Organklassesystem</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"206\" style=\"width:2.15in;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Bivirkninger</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"206\" style=\"width:154.2pt;border:solid windowtext 1.0pt;     border-left:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span lang=\"NO-BOK\">Frekvens</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                        </thead>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">InfeksiÃ¸se og   parasittÃ¦re sykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Herpes zoster</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ikke kjent**</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Sykdommer i   blod og lymfatiske organer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Lymfopeni</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Leukopeni</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Eosinofili</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Leukocytose</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Akutt   lymfatisk leukemi*</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Irreversibel   pancytopeni*</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt sjeldne</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt sjeldne</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Stoffskifte-   og ernÃ¦ringsbetingede sykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Nedsatt   appetitt</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Nevrologiske   sykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Hodepine</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Parestesi</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Svimmelhet*</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Progressiv   multifokal leukoencefalopati</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Mindre   vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ikke kjent</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Karsykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">RÃ¸dme/flushing</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Gastrointestinale   sykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">DiarÃ©</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Abdominal   distensjon</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Magesmerter</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Kvalme</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Oppkast</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Dyspepsi</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Forstoppelse</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ubehag i   magen</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Flatulens</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">SvÃ¦rt vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Hud- og   underhudssykdommer</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Erytem</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">FÃ¸lelse av   svie i huden</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">KlÃ¸e</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Allergisk   hudreaksjon</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Sjeldne</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Sykdommer i   nyre og urinveier</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Proteinuri</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Nyresvikt</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Fanconi-syndrom*</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Mindre   vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ikke kjent</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ikke kjent</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Generelle   lidelser og reaksjoner pÃ¥ administrasjonsstedet </span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Tretthet</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">VarmefÃ¸lelse</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Asteni</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                        <tr>\n                                            <td width=\"207\" style=\"width:155.35pt;border:solid windowtext 1.0pt;    border-top:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">UndersÃ¸kelser</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:2.15in;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ã˜kte   leverenzymer</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Ã˜kt   serumkreatinin</span>\n                                                </p>\n                                            </td>\n                                            <td width=\"206\" style=\"width:154.2pt;border-top:none;border-left:    none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Vanlige</span>\n                                                </p>\n                                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                    <span lang=\"NO-BOK\">Mindre   vanlige</span>\n                                                </p>\n                                            </td>\n                                        </tr>\n                                    </table>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">* Ytterligere bivirkninger rapportert med Fumaderm, et relatert legemiddel som inneholder dimetylfumarat samt andre fumarsyreestere.</span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">**Bivirkninger som ble rapportert  etter markedsfÃ¸ring.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Beskrivelse av utvalgte bivirkninger</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Gastrointestinale forstyrrelser</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Data fra den kliniske fase III-studien samt fra litteratur viser at gastrointestinale sykdommer med dimetylfumaratholdige legemidler mest sannsynlig oppstÃ¥r i lÃ¸pet av de fÃ¸rste 2 til 3 mÃ¥nedene etter at behandlingen er pÃ¥begynt. Ingen klar dosesammenheng  og ingen risikofaktorer for forekomst av disse bivirkningene kunne identifiseres. DiarÃ© var en vanlig bivirkning (36,9 %) blant pasienter som tok Acme Product, og dette fÃ¸rte til at legemidlet ble seponert hos omtrent 10 % av pasientene. Mer enn 9 % av disse diarÃ©hendelsene var av mild til moderat alvorlighetsgrad (se pkt. 4.4).</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">RÃ¸dme/flushing</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Basert pÃ¥ observasjoner i den klinske fase III-studien samt litteraturdata oppstÃ¥r rÃ¸dme oftest i lÃ¸pet av de fÃ¸rste ukene av behandlingen og har en tendens til Ã¥ reduseres over tid. I den kliniske studien opplevde totalt 20,8 % av pasientene som fikk Acme Product rÃ¸dme som var mild i de fleste tilfellene (se pkt. 4.4). Publisert klinisk erfaring med dimetylfumaratholdige legemidler viser at individuelle episoder med rÃ¸dme vanligvis begynner kort tid etter inntak av tablettene og opphÃ¸rer innen noen timer.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <i>\n                                            <span lang=\"NO-BOK\">Hematologiske forandringer</span>\n                                        </i>\n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Data fra den kliniske fase III-studien samt fra litteraturen viser\nat forandringer i hematologiske parametere mest sannsynlig forekommer i lÃ¸pet\nav de fÃ¸rste 3 mÃ¥nedene etter at behandlingen med dimetylfumarat er\npÃ¥begynt. Spesielt var det i den kliniske studien en lett reduksjon i\ngjennomsnittlige lymfocyttnivÃ¥er som begynte mellom uke 3 og 5 og var\nmaksimal innen uke 12, der omtrent en tredjedel av pasientene hadde\nlymfocyttverdier under 1,0 x 10\n                                            <sup>9</sup>/l. Gjennomsnitts- og\nmedianverdiene for lymfocytter forble innenfor normalomrÃ¥det i lÃ¸pet av den\nkliniske studien. Ved uke 16 (behandlingsslutt) var det ingen ytterligere\nreduksjon i lymfocyttallene. Ved uke 16 av behandlingen ble det vist at 13/175\n(7,4 %) av pasientene hadde lymfocyttnivÃ¥er &lt;0,7 x 10\n                                            <sup>9</sup>/l. BlodprÃ¸vetaking\nfor kliniske sikkerhetslaboratorietester ved oppfÃ¸lgingsbesÃ¸kene ble kun utfÃ¸rt\ni tilfelle uregelmessigheter ved forutgÃ¥ende besÃ¸k. I lÃ¸pet av den\nbehandlingsfrie oppfÃ¸lgingen ble det observert lymfocyttnivÃ¥er pÃ¥ &lt;0,7 x 10\n                                            <sup>9</sup>/l\nhos 1/29 (3,5 %) pasienter ved 6 mÃ¥neder og 0/28 (0 %) ved 12 mÃ¥neder\netter seponering av behandlingen. Ved 12 mÃ¥neder etter seponering av\nbehandlingen hadde 3/28 (10,7 %) pasienter lymfocyttverdier under 1,0 x 10\n                                            <sup>9</sup>/l,\nog dette ville representere 3/279 (1,1 %) av pasientene som begynte pÃ¥\nAcme Product.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">For det totale\nleukocyttallet ble en reduksjon vist ved uke 12 av behandlingen, det Ã¸kte\nlangsomt igjen ved uke 16 (behandlingsslutt), og 12 mÃ¥neder etter\nseponering av behandlingen hadde alle pasienter verdier over 3,0 x 10\n                                            <sup>9</sup>/l.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">En forbigÃ¥ende Ã¸kning i gjennomsnittsverdier for eosinofiler ble observert sÃ¥ tidlig som uke 3, nÃ¥dde maksimal verdi ved uke 5 og 8,og hadde returnert til baselineverdier ved uke 16.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">For overvÃ¥kningsanbefalinger og klinisk hÃ¥ndtering av hematologiske bivirkninger, se pkt 4.4.</span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                </div>"
         ];
         fhir:Composition.section.section [
           fhir:index 0;
           fhir:Element.id [ fhir:value "267ecb50-3623-4dbe-8071-840f0ca2889b" ];
           fhir:Composition.section.title [ fhir:value "Melding av mistenkte bivirkninger" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "29" ];
               fhir:Coding.display [ fhir:value "Melding av mistenkte bivirkninger" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Melding av mistenkte bivirkninger etter godkjenning av legemidlet\ner viktig. Det gjÃ¸r det mulig Ã¥ overvÃ¥ke forholdet mellom nytte og risiko for\nlegemidlet kontinuerlig. Helsepersonell oppfordres til Ã¥ melde enhver mistenkt\nbivirkning. Dette gjÃ¸res \n                                                <span style=\"color:black\">via \n                                                    <span style=\"background:  lightgrey\">det nasjonale meldesystemet som beskrevet i </span>\n                                                </span>\n                                            </span>\n                                            <span lang=\"EN-GB\">\n                                                <a href=\"http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc\">\n                                                    <span style=\"background:lightgrey\">Appendix V</span>\n                                                </a>\n                                            </span>\n                                            <span lang=\"NO-BOK\">.</span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ]
       ], [
         fhir:index 8;
         fhir:Element.id [ fhir:value "68f3502a-0e58-4cab-a49a-e9c68496e1df" ];
         fhir:Composition.section.title [ fhir:value "4.9     Overdosering" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "30" ];
             fhir:Coding.display [ fhir:value "4.9 Overdosering" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Symptomatisk behandling er indisert ved overdosering. Ingen spesifikk motgift er kjent.</span>\n                                    </p>\n                                    \n                                    \n                                </div>"
         ]
       ]
     ], [
       fhir:index 4;
       fhir:Element.id [ fhir:value "bfaa811c-6b32-4216-be85-3cb156c82bb2" ];
       fhir:Composition.section.title [ fhir:value "5.       FARMAKOLOGISKE EGENSKAPER" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "32" ];
           fhir:Coding.display [ fhir:value "5. FARMAKOLOGISKE EGENSKAPER" ]
         ]
       ];
       fhir:Composition.section.section [
         fhir:index 0;
         fhir:Element.id [ fhir:value "5f641461-bcca-46a8-8bfe-4838ebf7bf99" ];
         fhir:Composition.section.title [ fhir:value "5.1     Farmakodynamiske egenskaper" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "33" ];
             fhir:Coding.display [ fhir:value "5.1 Farmakodynamiske egenskaper" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Farmakoteraputisk gruppe: Andre immunsuppressiver, ATC-kode: L04AX07</span>\n                                    </p>\n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\"/>\n                                        \n                                    </p>\n                                </div>"
         ];
         fhir:Composition.section.section [
           fhir:index 0;
           fhir:Element.id [ fhir:value "5b40031c-aad3-4fc1-b495-9683f84496ec" ];
           fhir:Composition.section.title [ fhir:value "Virkningsmekanisme" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "34" ];
               fhir:Coding.display [ fhir:value "Virkningsmekanisme" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">De antiinflammatoriske og immunmodulerende effektene av dimetylfumarat og dets metabolitt monometylfumarat er ikke fullt ut klarlagt, men antas hovedsakelig Ã¥ vÃ¦re grunnet interaksjon med intracellulÃ¦rt redusert glutation i celler som er direkte involvert i patogenesen ved psoriasis. Denne interaksjonen med glutation fÃ¸rer til hemming av translokasjon inn i kjernen, og den transkripsjonelle aktiviteten til nukleÃ¦r faktor kappa-lettkjede-enhancer av aktiverte B-celler (NF-ÎºB). </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Den primÃ¦re aktiviteten av dimetylfumarat og monometylfumarat anses Ã¥ vÃ¦re immunmodulerende, noe som resulterer i en endring av T-hjelperceller (Th) fra Th1- og Th17-profil til en Th2-fenotype. Inflammatorisk cytokinproduksjon reduseres ved induksjon av proapoptotiske hendelser, hemming av keratinocytt-proliferasjon, redusert uttrykk av adhesjonsmolekyler og redusert inflammatorisk infiltrat i psoriasisplakk. </span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\"/>\n                                            \n                                        </p>\n                                    </div>"
           ]
         ], [
           fhir:index 1;
           fhir:Element.id [ fhir:value "16cf40c8-e667-431a-a1b0-8dc621a4a1c3" ];
           fhir:Composition.section.title [ fhir:value "Klinisk effekt og sikkerhet" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "36" ];
               fhir:Coding.display [ fhir:value "Klinisk effekt og sikkerhet" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Sikkerhet og effekt av Acme Product ble undersÃ¸kt i en dobbeltblindet, 3-armet fase III-studie (1102) med placebo og aktiv komparator</span>\n                                            <span lang=\"NO-BOK\">kontroll</span>\n                                            <span lang=\"NO-BOK\">med pasienter med moderat til alvorlig plakkpsoriasis (studie 1102). I studien ble 704 pasienter  randomisert til Acme Product, en aktiv komparator (Fumaderm, et kombinasjonspreparat med samme innhold av dimetylfumarat pluss 3 monoetylfumaratsalter) og placebo i et forhold pÃ¥ 2:2:1. Pasienter begynte behandling med tabletter med innhold 30 mg/dag dimetylfumarat eller placebo, og titrering opp til maksimalt 720 mg/dag i begge aktive behandlingsarmer som beskrevet i pkt. 4.2. Dersom behandlingseffekt ble observert fÃ¸r maksimaldosen pÃ¥ dimetylfumarat 720 mg/dag var nÃ¥dd, var det unÃ¸dvendig med en ytterligere Ã¸kning av dosen, og dosen skulle reduseres jevnt til en individuell vedlikeholdsdose. Ved individuell intolerabilitet ved Ã¸kt dosering i lÃ¸pet av uke 4 til 16, skulle pasienten gÃ¥ tilbake til den siste tolererte dosen tatt siden start av uke 4, og som skulle opprettholdes inntil slutten av behandlingsperioden (uke 16). Pasientene mottok behandling i opp til 16 uker og oppfÃ¸lgingsbesÃ¸k var planlagt for opp til 12 mÃ¥neder etter avsluttet behandling.</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Det var god balanse i demografiske og baselineparametre mellom behandlingsgruppene. Av de 699 pasientene var de fleste var kaukasiere (99 %) og menn (65 %), og gjennomsnittsalderen var 44 Ã¥r. De fleste pasientene (91 %) var &lt;65 Ã¥r. De fleste pasientene hadde moderat psoriasis basert pÃ¥ PASI-skÃ¥r for psoriasisomrÃ¥de og alvorlighetsgrad (Psoriasis Area and Severity Index) og PGAI-skÃ¥r for legens totalvurdering (Physicianâ€™s Global Assessment) ved baseline: gjennomsnittlig PASI-skÃ¥r ved baseline var 16,35 og 60 % av pasientene ble scoret som moderat pÃ¥ PGA. Flertallet av pasientene rapporterte en &quot;svÃ¦rt hÃ¸y&quot; eller &quot;ekstremt hÃ¸y&quot; pÃ¥virkning av psoriasis pÃ¥ sitt liv basert pÃ¥ Dermatologisk livskvalitetsindeks (DLQI), med en gjennomsnittlig DLQI-skÃ¥r pÃ¥ 11,5. </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal;text-autospace:none\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Etter 16 ukers behandling ble Acme Product funnet Ã¥ vÃ¦re bedre enn placebo (p &lt;0,0001) basert pÃ¥ PASI 75 og PGA-skÃ¥r pÃ¥ helet eller nesten tilhelet, og ikke dÃ¥rligere (ved bruk av en non-inferioritymargin pÃ¥ 15 %) enn den aktive komparatoren (p &lt;0,0003) basert pÃ¥ PASI 75.</span>\n                                        </p>\n                                        \n                                        <table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"612\" style=\"border-collapse:collapse\" class=\"MsoNormalTable\">\n                                            <tr>\n                                                <td colspan=\"7\" width=\"612\" style=\"width:459.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">Oppsummering av klinisk effekt etter 16   ukers behandling i studie 1102</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">Vurdering</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"123\" style=\"width:92.15pt;border:none;    border-top:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Acme Product</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"95\" style=\"width:70.9pt;border:none;border-top:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Placebo</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"123\" style=\"width:92.1pt;border:none;border-top:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Fumaderm</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    \n                                                </td>\n                                                <td colspan=\"2\" width=\"123\" style=\"width:92.15pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">N=267</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"95\" style=\"width:70.9pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">N=131</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td width=\"123\" style=\"width:92.1pt;border:none;border-bottom:solid windowtext 1.0pt;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">N=273</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"7\" width=\"612\" style=\"width:459.0pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">Superiority testing kontra placebo</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:justify;text-justify:inter-ideograph;    line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">PASI 75</span>\n                                                        </b>\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">, n (%)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"123\" style=\"width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">100 (37,5)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"95\" style=\"width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">20 (15,3)</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"123\" style=\"width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">110 (40,3)</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">p-verdi</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-right:15.85pt;text-align:right;    line-height:normal\" align=\"right\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">&lt;0,0001\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:15.85pt;line-height:normal\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">&lt;0,0001\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"SV\">Tosidig 99,24 % KI</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid\" align=\"right\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:    10.0pt\" lang=\"IT\">10,7, 33,7\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:8.75pt;line-height:normal\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"IT\">13,5, 36,6</span>\n                                                        <sup>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">a</span>\n                                                        </sup>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">PGA-skÃ¥r helet eller nesten helet,</span>\n                                                        </b>\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">n (%)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"123\" style=\"width:92.15pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">88 (33,0)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"95\" style=\"width:70.9pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">17 (13,0)</span>\n                                                    </p>\n                                                </td>\n                                                <td width=\"123\" style=\"width:92.1pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">102 (37,4)</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">p-verdi</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.6pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-right:15.85pt;text-align:right;    line-height:normal\" align=\"right\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">&lt;0,0001\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.55pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:15.85pt;line-height:normal\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">&lt;0,0001\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"width:203.85pt;border:none;border-bottom:    solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Tosidig 99.24%KI</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.6pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-right:14.2pt;text-align:right;    line-height:normal;page-break-after:avoid\" align=\"right\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:    10.0pt\" lang=\"EN-GB\">9,0, 31,0\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"170\" style=\"width:127.55pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:8.75pt;line-height:normal\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">13,3, 35,5\n                                                            <sup>a</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    \n                                                </td>\n                                                <td colspan=\"3\" width=\"142\" style=\"width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Acme Product</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"151\" style=\"width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Fumaderm</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    \n                                                </td>\n                                                <td colspan=\"3\" width=\"142\" style=\"width:106.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">N=267</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"151\" style=\"width:113.4pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">N=273</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">Non-inferiority av   Acme Product kontra Fumaderm</span>\n                                                        </b>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"142\" style=\"width:106.3pt;border:none;    padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\"/>\n                                                </td>\n                                                <td colspan=\"2\" width=\"151\" style=\"width:113.4pt;border:none;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\"/>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"EN-GB\">PASI 75</span>\n                                                        </b>\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">, n (%)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"142\" style=\"width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">100 (37,5)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"151\" style=\"width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">110 (40,3)</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">p-verdi</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"5\" width=\"293\" style=\"width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">0,0003\n                                                            <sup>b</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">Ensidig 97,5 % gjentatt KI   (nedre grense)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"5\" width=\"293\" style=\"width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">-11,6\n                                                            <sup>b</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <b>\n                                                            <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">PGA-skÃ¥r helet eller   nesten helet </span>\n                                                        </b>\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">n (%)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"3\" width=\"142\" style=\"width:106.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">88 (33,0)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"2\" width=\"151\" style=\"width:113.4pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">102 (37,4)</span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">p-verdi</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"5\" width=\"293\" style=\"width:219.7pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">0,0007\n                                                            <sup>b</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"2\" width=\"319\" style=\"width:239.3pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"margin-left:7.1pt;line-height:normal;page-break-after:    avoid\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"NO-BOK\">Ensidig 97,5 % gjentatt KI   (nedre grense)</span>\n                                                    </p>\n                                                </td>\n                                                <td colspan=\"5\" width=\"293\" style=\"width:219.7pt;border:none;    border-bottom:solid windowtext 1.0pt;padding:1.4pt 5.4pt 1.4pt 5.4pt\" valign=\"top\">\n                                                    <p style=\"text-align:center;line-height:normal;    page-break-after:avoid\" align=\"center\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:10.0pt\" lang=\"EN-GB\">13,0\n                                                            <sup>b</sup>\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td colspan=\"7\" width=\"612\" style=\"width:459.0pt;border:none;    padding:0in 5.4pt 0in 5.4pt\" valign=\"top\">\n                                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">Fumaderm = Aktiv komparator = et kombinasjonspreparat   med samme innhold av dimetylfumarat pluss 3 monoetylhydrogenfumaratsalter;</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">n </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">= </span>\n                                                        <span style=\"font-size:    9.0pt\" lang=\"NO-BOK\">antall pasienter med tilgjengelige data</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">;</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">N </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">= </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">antall </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">pasienter</span>\n                                                        <span style=\"font-size:    9.0pt\" lang=\"NO-BOK\">i </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">populasjon</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">; PASI </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">= </span>\n                                                        <span style=\"font-size:    9.0pt\" lang=\"NO-BOK\">Psoriasis Area Severity Index</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">;</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">PGA </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">= </span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">Physicianâ€™s Global Assessment</span>\n                                                        <span style=\"font-size:9.0pt\" lang=\"NO-BOK\">; \n                                                            <sup>a</sup>Overlegenhet for\nAcme Product kontra placebo med en differanse pÃ¥ 22,2 % for PASI 75 og 20,0 %\nfor PGA-skÃ¥r helet eller nesten helet, overlegenhet av Fumaderm kontra\nplacebo med en differanse pÃ¥ 25,0 % for PASI og 24,4 % for PGA-skÃ¥r helet eller\nnesten helet.\n                                                            <sup>b</sup>Non-inferiority  av Acme Product kontra Fumaderm med\nen differanse pÃ¥ -2,8 % for PASI 75 og -4,4 % for PGA-skÃ¥r helet eller nesten\nhelet.\n                                                        </span>\n                                                    </p>\n                                                </td>\n                                            </tr>\n                                            <tr>\n                                                <td width=\"272\" style=\"border:none\"/>\n                                                <td width=\"47\" style=\"border:none\"/>\n                                                <td width=\"76\" style=\"border:none\"/>\n                                                <td width=\"47\" style=\"border:none\"/>\n                                                <td width=\"19\" style=\"border:none\"/>\n                                                <td width=\"28\" style=\"border:none\"/>\n                                                <td width=\"123\" style=\"border:none\"/>\n                                            </tr>\n                                        </table>\n                                        <p style=\"line-height:normal;text-autospace:none\" class=\"MsoNormal\"/>\n                                        <p style=\"line-height:normal;text-autospace:none\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Det var en trend i effektendepunktet PASI-skÃ¥r gjennomsnittlig -% endring fra baseline, som indikerte begynnelsen av klinisk respons pÃ¥ Acme Product sÃ¥ tidlig som uke 3 (-11,8 %) som ble statistisk signifikant sammenlignet med placebo innen uke 8 (-30,9 %). Ytterligere forbedring ble sett innen uke 16 (-50,8 %).</span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <a name=\"_Ref431313822\"/>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Fordelene ved behandling med Acme Product ble ogsÃ¥ stÃ¸ttet av pasientenes selvopplevde forbedringer i livskvaliteten. I uke 16 hadde pasienter som ble behandlet med Acme Product en lavere gjennomsnittlig DLQI sammenlignet med placebo (5,4 kontra 8,8). </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Tilbakefall (definert som forverring pÃ¥ &gt;125 % av baseline PASI-verdi) ble vurdert etter 2 mÃ¥neder uten behandling og viste seg Ã¥ ikke vÃ¦re et klinisk problem med fumarsyreestere, da det ble dokumentert hos svÃ¦rt fÃ¥ pasienter (Acme Product 1,1 % og aktiv komparator 2,2 %, sammenlignet med 9,3 % i placebogruppen).</span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Langsiktige effektdata er for tiden ikke tilgjengelige for Acme Product, men i farmakokinetiske og kliniske studier viste systemisk eksponering, effekt og sikkerhet seg Ã¥ vÃ¦re sammenlignbare for Acme Product og den aktive komparatoren som inneholder dimetylfumarat. Dermed er det rimelig Ã¥ forvente at langsiktig effekt ogsÃ¥ er sammenlignbar for Acme Product og dimetylfumaratholdige legemidler. Opprettholdelse av langsiktig effekt har blitt godt beskrevet for andre dimetylfumaratholdige legemidler, og derfor kan det forventes at behandlingsfordelene som ses med Acme Product ved uke 16, opprettholdes hos pasienter som behandles pÃ¥ lang sikt, i minst 24 mÃ¥neder.</span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ], [
           fhir:index 2;
           fhir:Element.id [ fhir:value "b54479b6-e871-407c-af15-0aba326b4513" ];
           fhir:Composition.section.title [ fhir:value "Pediatrisk populasjon" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "37" ];
               fhir:Coding.display [ fhir:value "Pediatrisk populasjon" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Det europeiske legemiddelkontoret har gitt unntak fra forpliktelsen til Ã¥ presentere resultater fra studier med Acme Product i alle undergrupper av den pediatriske populasjonen ved denne indikasjonen (se pkt. 4.2 for informasjon om pediatrisk bruk).</span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ]
       ], [
         fhir:index 1;
         fhir:Element.id [ fhir:value "a41f9de8-182e-456c-b2ef-e1d03a91da29" ];
         fhir:Composition.section.title [ fhir:value "5.2     Farmakokinetiske egenskaper" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "38" ];
             fhir:Coding.display [ fhir:value "5.2 Farmakokinetiske egenskaper" ]
           ]
         ];
         fhir:Composition.section.section [
           fhir:index 0;
           fhir:Element.id [ fhir:value "59ed6059-97ef-4228-b72b-7167ecbe8213" ];
           fhir:Composition.section.title [ fhir:value "Absorpsjon" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "39" ];
               fhir:Coding.display [ fhir:value "Absorpsjon" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Etter oral administrasjon pÃ¥vises ikke dimetylfumarat i plasma fordi det raskt hydrolyseres av esteraser til sin aktive metabolitt monometylfumarat. Etter oral administrering av en enkelt tablett Acme Product pÃ¥ 120 mg til friske forsÃ¸kspersoner, nÃ¥dde monometylfumarat maksimal plasmakonsentrasjoner pÃ¥ rundt 1325 ng/ml og 1311 ng/ml etter henholdsvis faste og matinntak. NÃ¥r Acme Product tas sammen med mat </span>\n                                            <span lang=\"NO-BOK\">forsinkes</span>\n                                            <span lang=\"NO-BOK\">t\n                                                <sub>max</sub>for monometylfumarat fra 3,5 til 9,0 timer.\n                                            </span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ], [
           fhir:index 1;
           fhir:Element.id [ fhir:value "a2dd0a8f-9f20-425e-baa7-3d807b818e6b" ];
           fhir:Composition.section.title [ fhir:value "Distribusjon" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "40" ];
               fhir:Coding.display [ fhir:value "Distribusjon" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Plasmaproteinbindingen av monometylfumarat er omkring 50 %. Dimetylfumarat viser ikke noen bindingsaffinitet til serumproteiner som ytterligere kan bidra til dets hurtige eliminasjon fra sirkulasjonen. </span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ], [
           fhir:index 2;
           fhir:Element.id [ fhir:value "564cb153-58a2-49ee-a6e2-bd5a5a9ae05f" ];
           fhir:Composition.section.title [ fhir:value "Biotransformasjon" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "41" ];
               fhir:Coding.display [ fhir:value "Biotransformasjon" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Biotransformasjonen av dimetylfumarat involverer ikke cytokrom\nP450-isoenzymer. \n                                                <i>In vitro</i>-studier har vist at monometylfumarat ved\nterapeutisk dose ikke hemmer eller induserer noen av cytokrom P450-enzymene,\nden er ikke et substrat eller hemmer av P-glykoprotein og er ikke en hemmer av\nde mest vanlige effluks- og opptakstransportÃ¸rene.\n                                                <i>In vitro</i>-studier har\nvist at dimetylfumarat ved en terapeutisk dose ikke hemmer CYP3A4/5 og BCRP og\ner en svak P-glykoproteininibitor.\n                                            </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" id=\"7fa270b4-18aa-4b54-961c-e77d0a6b05b8\" class=\"MsoNormal\"/>\n                                        <i>\n                                            <span lang=\"NO-BOK\">In vitro</span>\n                                        </i>\n                                        \n                                        <p style=\"line-height:normal\" id=\"7fa270b4-18aa-4b54-961c-e77d0a6b05b8\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">-studier har vist at hydrolyse av dimetylfumarat til monometylfumarat skjer raskt ved pHÂ 8 (pH i tynntarmen), men ikke ved pHÂ 1 (pH i magesekken). En del av det totale dimetylfumaratet blir hydrolysert av esteraser og tynntarmens alkaliske miljÃ¸, mens resten kommer inn i portveneblodet. Videre studier har vist at dimetylfumarat (og i mindre grad monometylfumarat) reagerer delvis med redusert glutation som danner en glutationforbindelse. Disse forbindelsene ble pÃ¥vist i dyrestudier i tarmslimhinner hos rotter og i mindre grad i portveneblod. Ukonjugert dimetylfumarat kan imidlertid ikke pÃ¥vises i plasma hos dyr eller psoriasispasienter etter oral administrering. Derimot kan ukonjugert monometylfumarat pÃ¥vises i plasma. Videre metabolisme skjer ved oksideringen via trikarboksylsyresyklusen, som danner karbondioksid og vann. </span>\n                                        </p>\n                                        <p style=\"margin-right:-.1pt;line-height:normal\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\"/>\n                                            \n                                        </p>\n                                    </div>"
           ]
         ], [
           fhir:index 3;
           fhir:Element.id [ fhir:value "ecca1616-154d-4478-91e8-cf9be6418312" ];
           fhir:Composition.section.title [ fhir:value "Eliminasjon" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "42" ];
               fhir:Coding.display [ fhir:value "Eliminasjon" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">UtÃ¥nding av CO\n                                                <sub>2</sub>som fÃ¸lge av monometylfumaratets\nmetabolisme er den primÃ¦re eliminasjonsveien. Bare smÃ¥ mengder intakt\nmonometylfumarat skilles ut gjennom urin eller avfÃ¸ring. Den delen av\ndimetylfumaratet som reagerer med glutation, med dannelse av en\nglutationforbindelse, metaboliseres videre til merkaptopurinsyre, som utskilles\ni urinen.\n                                            </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Den tilsynelatende terminale eliminasjonshalveringstiden for monometylfumaratet er omtrent 2 timer.</span>\n                                        </p>\n                                        \n                                    </div>"
           ]
         ], [
           fhir:index 4;
           fhir:Element.id [ fhir:value "91f77a7f-6acc-4ef9-8796-7d1e20bd8325" ];
           fhir:Composition.section.title [ fhir:value "Linearitet/ikke-linearitet" ];
           fhir:Composition.section.code [
             fhir:CodeableConcept.coding [
               fhir:index 0;
               fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
               fhir:Coding.code [ fhir:value "43" ];
               fhir:Coding.display [ fhir:value "Linearitet/ikke-linearitet" ]
             ]
           ];
           fhir:Composition.section.text [
             fhir:Narrative.status [ fhir:value "additional" ];
             fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Til tross for hÃ¸y variasjon mellom pasienter, var eksponeringen\nmÃ¥lt som AUC og C\n                                                <sub>max</sub>, generelt doseproporsjonal etter administrering\nav enkeltdoser pÃ¥ 4 x 30 mg dimetylfumarat tabletter (total dose pÃ¥ 120 mg)\nog 2 x 120 mg dimetylfumarat tabletter (total dose pÃ¥ 240 mg).\n                                            </span>\n                                        </p>\n                                        <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\"/>\n                                            \n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\">Nedsatt nyrefunksjon</span>\n                                            \n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Ingen spesifikke studier har blitt utfÃ¸rt hos pasienter med nedsatt nyrefunksjon. Men fordi eliminasjon via nyrene spiller en mindre rolle for totalclearance fra plasma, er det usannsynlig at nedsatt nyrefunksjon kan pÃ¥virke de farmakokinetiske egenskapene til Acme Product (se pkt. 4.2). </span>\n                                        </p>\n                                        \n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            \n                                                <span lang=\"NO-BOK\">Nedsatt leverfunksjon</span>\n                                            \n                                        </p>\n                                        <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                            <span lang=\"NO-BOK\">Ingen spesifikke studier har blitt utfÃ¸rt hos pasienter med nedsatt leverfunksjon. Men ettersom dimetylfumarat metaboliseres av esteraser og det alkaliske miljÃ¸et i tynntarmen uten at cytokrom P450 er involvert, forventes det ikke at nedsatt leverfunksjon pÃ¥virker eksponering (se pkt. 4.2). </span>\n                                        </p>\n                                        <p style=\"margin-right:-.1pt;line-height:normal\" class=\"MsoNormal\"/>\n                                    </div>"
           ]
         ]
       ], [
         fhir:index 2;
         fhir:Element.id [ fhir:value "c83d8044-45f8-43dc-b493-e9f29a019451" ];
         fhir:Composition.section.title [ fhir:value "5.3     Prekliniske sikkerhetsdata" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "45" ];
             fhir:Coding.display [ fhir:value "5.3 Prekliniske sikkerhetsdata" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Prekliniske sikkerhetsfarmakologi- og gentoksisitetsdata indikerer ingen spesiell fare for mennesker.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Toksikologi</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Nyrene ble identifisert som et viktig mÃ¥lorgan for toksisitet i\nprekliniske studier. Nyrefunn hos hunder omfattet minimal til moderat tubulÃ¦r hypertrofi,\nÃ¸kt forekomst og alvorlighetsgrad av tubulÃ¦r vakuolisering og minimal til liten\ndegenerering av nyretubuli, og dette ble ansett som toksikologisk relevant. HÃ¸yeste\nnivÃ¥ uten observerte bivirkninger (NOAEL, noâ€‘observed\nadverse-effect-level) etter 3 mÃ¥neders behandling var 30 mg/kg/dag, noe\nsom tilsvarer 2,9 ganger og 9,5 ganger human systemisk eksponering\nved hÃ¸yeste anbefalte dose (720 mg/dag), for henholdsvis AUC- og C\n                                            <sub>max</sub>-verdier.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Reproduksjonstoksisitet </span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ingen studier av fertilitet eller pre- og postnatal utvikling er blitt utfÃ¸rt med Acme Product.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det var ingen\neffekt pÃ¥ fostervekt eller misdannelser som kunne knyttes til maternelt inntak\nav dimetylfumarat under studien av embryofÃ¸tal utvikling hos rotter. Imidlertid\nvar det en Ã¸kning i antall fostre med avvikene &quot;ekstra leverlapp&quot; og\n&quot;unormal hoftekamjustering&quot; med maternelt toksiske doser. NOAEL for\nmaternell og embryofÃ¸tal toksisitet var 40 mg/kg/dag, som tilsvarer 0,2 ganger\nog 2,0 ganger human systemisk eksponering ved hÃ¸yeste anbefalte dose\n(720 mg/dag), for henholdsvis AUC- og C\n                                            <sub>max</sub>-verdier.\n                                        </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Det er vist at dimetylfumarat passerer placentamembranen til fÃ¸talt blod hos rotter.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Karsinogenisitet</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ingen karsinogenisitetsstudier er utfÃ¸rt for Acme Product. Basert pÃ¥ tilgjengelige data som indikerer at fumarsyreestere kan aktivere cellulÃ¦re mekanismer relatert til utvikling av nyretumorer, kan en potensiell tumorigen aktivitet av eksogent administrert dimetylfumarat pÃ¥ nyrene ikke utelukkes.</span>\n                                    </p>\n                                    \n                                    \n                                </div>"
         ]
       ]
     ], [
       fhir:index 5;
       fhir:Element.id [ fhir:value "d3f0286b-3050-4928-b713-0294beb4cb15" ];
       fhir:Composition.section.title [ fhir:value "6.       FARMASÃ˜YTISKE OPPLYSNINGER" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "47" ];
           fhir:Coding.display [ fhir:value "6. FARMASÃ˜YTISKE OPPLYSNINGER" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <b>\n                                        <span lang=\"NO-BOK\">6.1     Fortegnelse over hjelpestoffer</span>\n                                    </b>\n                                </p>\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 30 mg og Acme Product 120 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <i>\n                                        <span lang=\"NO-BOK\">Kjerne:</span>\n                                    </i>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Laktosemonohydrat</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Mikrokrystallinsk cellulose</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Krysskarmellosenatrium</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Kolloidal vannfri silika</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Magnesiumstearat</span>\n                                </p>\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <i>\n                                        <span lang=\"NO-BOK\">Drasjering:</span>\n                                    </i>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Metakrylsyreetylakrylatkopolymer (1:1) </span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Talkum</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Trietylsitrat</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Titandioksid (E171)</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Simetikon</span>\n                                </p>\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    \n                                        <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                    \n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <i>\n                                        <span lang=\"NO-BOK\">Drasjering:</span>\n                                    </i>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Metakrylsyreetylakrylatkopolymer (1:1) </span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Talkum</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Trietylsitrat</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Titandioksid (E171)</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Simetikon</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Indigokarmin (E132)</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Natriumhydroksid</span>\n                                </p>\n                                \n                            </div>"
       ];
       fhir:Composition.section.section [
         fhir:index 0;
         fhir:Element.id [ fhir:value "9c73367e-0062-48a7-a22c-325e1df72da9" ];
         fhir:Composition.section.title [ fhir:value "6.2     Uforlikeligheter" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "49" ];
             fhir:Coding.display [ fhir:value "6.2 Uforlikeligheter" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ikke relevant.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 1;
         fhir:Element.id [ fhir:value "c5de1b87-c384-4acd-b513-358efd62c979" ];
         fhir:Composition.section.title [ fhir:value "6.3     Holdbarhet" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "50" ];
             fhir:Coding.display [ fhir:value "6.3 Holdbarhet" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">3 Ã¥r.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 2;
         fhir:Element.id [ fhir:value "09bc5d7a-aa2b-4030-bbf0-186dc3872257" ];
         fhir:Composition.section.title [ fhir:value "6.4     Oppbevaringsbetingelser" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "51" ];
             fhir:Coding.display [ fhir:value "6.4 Oppbevaringsbetingelser" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Dette legemidlet krever ingen spesielle oppbevaringsbetingelser.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 3;
         fhir:Element.id [ fhir:value "788b714e-99f5-4838-9d3d-c2278e3e5f06" ];
         fhir:Composition.section.title [ fhir:value "6.5     Emballasje (type og innhold)" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "52" ];
             fhir:Coding.display [ fhir:value "6.5 Emballasje (type og innhold) <og spesielt utstyr for bruk, administrering eller implantasjon>" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Acme Product 30 mg</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">42, 70 og 210 enterotabletter i PVC/PVDC blisterpakninger av aluminium. </span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        \n                                            <span lang=\"NO-BOK\">Acme Product 120 mg</span>\n                                        \n                                    </p>\n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">40, 70, 90, 100, 120, 180, 200, 240, 300, 360 og 400 enterotabletter i PVC/PVDC blisterpakninger av aluminium.</span>\n                                    </p>\n                                    \n                                    <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ikke alle pakningsstÃ¸rrelser vil nÃ¸dvendigvis bli markedsfÃ¸rt.</span>\n                                    </p>\n                                    \n                                </div>"
         ]
       ], [
         fhir:index 4;
         fhir:Element.id [ fhir:value "08b14b4e-bbe6-426c-be2c-0c9e1b6b6347" ];
         fhir:Composition.section.title [ fhir:value "6.6     Spesielle forholdsregler for destruksjon" ];
         fhir:Composition.section.code [
           fhir:CodeableConcept.coding [
             fhir:index 0;
             fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
             fhir:Coding.code [ fhir:value "53" ];
             fhir:Coding.display [ fhir:value "6.6 Spesielle forholdsregler for destruksjon <og annen hÃ¥ndtering>" ]
           ]
         ];
         fhir:Composition.section.text [
           fhir:Narrative.status [ fhir:value "additional" ];
           fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                    \n                                    <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                        <span lang=\"NO-BOK\">Ingen spesielle forholdsregler for destruksjon.</span>\n                                    </p>\n                                    \n                                    \n                                </div>"
         ]
       ]
     ], [
       fhir:index 6;
       fhir:Element.id [ fhir:value "ab1e079a-7e7b-459a-9687-94a2a7b20abe" ];
       fhir:Composition.section.title [ fhir:value "7.       INNEHAVER AV MARKEDSFÃ˜RINGSTILLATELSEN" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "55" ];
           fhir:Coding.display [ fhir:value "7. INNEHAVER AV MARKEDSFÃ˜RINGSTILLATELSEN" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Almirall, S.A.</span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Ronda General Mitre, 151</span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">08022 Barcelona</span>\n                                </p>\n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Spania</span>\n                                </p>\n                                \n                                \n                            </div>"
       ]
     ], [
       fhir:index 7;
       fhir:Element.id [ fhir:value "e2f48221-aa2b-4a2a-828a-6a1fe1926ff8" ];
       fhir:Composition.section.title [ fhir:value "8.       MARKEDSFÃ˜RINGSTILLATELSESNUMMER (NUMRE)" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "56" ];
           fhir:Coding.display [ fhir:value "8. MARKEDSFÃ˜RINGSTILLATELSESNUMMER (NUMRE)" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"ES\">EU/1/17/1201/001\n                                        <br/>\nEU/1/17/1201/002\n                                        <br/>\nEU/1/17/1201/003\n                                        <br/>\nEU/1/17/1201/004\n                                        <br/>\nEU/1/17/1201/005\n                                        <br/>\nEU/1/17/1201/006\n                                        <br/>\n                                    </span>\n                                    <span lang=\"ES\">EU/1/17/1201/007\n                                        <br/>\n                                    </span>\n                                    <span lang=\"ES\">EU/1/17/1201/008\n                                        <br/>\nEU/1/17/1201/009\n                                        <br/>\n                                    </span>\n                                    <span lang=\"ES\">EU/1/17/1201/010\n                                        <br/>\nEU/1/17/1201/011\n                                    </span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"ES\">EU/1/17/1201/012</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"ES\">EU/1/17/1201/013</span>\n                                </p>\n                                <p style=\"line-height:normal\" class=\"MsoNormal\">\n                                    <span lang=\"ES\">EU/1/17/1201/014</span>\n                                </p>\n                                \n                                \n                                \n                            </div>"
       ]
     ], [
       fhir:index 8;
       fhir:Element.id [ fhir:value "5b69e508-14f8-46fe-8eb4-e9bc863b2fd7" ];
       fhir:Composition.section.title [ fhir:value "9.       DATO FOR FÃ˜RSTE MARKEDSFÃ˜RINGSTILLATELSE /SISTE FORNYELSE" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "57" ];
           fhir:Coding.display [ fhir:value "9. DATO FOR FÃ˜RSTE MARKEDSFÃ˜RINGSTILLATELSE / SISTE FORNYELSE" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Dato for fÃ¸rste markedsfÃ¸ringstillatelse: 23. juni 2017</span>\n                                </p>\n                                \n                                \n                            </div>"
       ]
     ], [
       fhir:index 9;
       fhir:Element.id [ fhir:value "0293fe81-3702-4b3b-94fa-4c478cfb6da6" ];
       fhir:Composition.section.title [ fhir:value "10.     OPPDATERINGSDATO" ];
       fhir:Composition.section.code [
         fhir:CodeableConcept.coding [
           fhir:index 0;
           fhir:Coding.system [ fhir:value "http://spor.ema.europa.eu/v1/example-sections" ];
           fhir:Coding.code [ fhir:value "58" ];
           fhir:Coding.display [ fhir:value "10. OPPDATERINGSDATO" ]
         ]
       ];
       fhir:Composition.section.text [
         fhir:Narrative.status [ fhir:value "additional" ];
         fhir:Narrative.div "<div xmlns=\"http://www.w3.org/1999/xhtml\">\n                                \n                                <p style=\"line-height:normal;page-break-after:avoid\" class=\"MsoNormal\">\n                                    <span lang=\"NO-BOK\">Detaljert informasjon er tilgjengelig pÃ¥ nettstedet til Det europeiske legemiddelkontoret (The European Medicines Agency) </span>\n                                    <span lang=\"EN-GB\">\n                                        <a href=\"http://www.ema.europa.eu\">\n                                            <span lang=\"NO-BOK\">http://www.ema.europa.eu</span>\n                                        </a>\n                                    </span>\n                                    <span style=\"color:blue\" lang=\"NO-BOK\">.</span>\n                                </p>\n                                <p style=\"margin-right:-.1pt;line-height:normal\" class=\"MsoNormal\"/>\n                                <span style=\"font-size:11.0pt;font-family:&quot;Times New Roman&quot;,serif\" lang=\"NO-BOK\">\n                                    <br style=\"page-break-before:always\"/>\n                                </span>\n                            </div>"
       ]
     ]
  ] .

# - ontology header ------------------------------------------------------------

<http://hl7.eu/fhir/ig/gravitate-health/Bundle/995d3971-b899-43bf-857d-98c26634796d.ttl> a owl:Ontology;
  owl:imports fhir:fhir.ttl .

# -------------------------------------------------------------------------------------

